

# BRADEN MANNNS, MD, MSc, FRCPC

## I. Biographical Data

Work address: Foothills Medical Centre  
1403 – 29<sup>th</sup> Street, NW  
Calgary, Alberta, Canada  
T2N 2T9  
403-944-2595 (phone)  
403-944-2876 (fax)  
Braden.Mannns@albertahealthservices.ca

Date of birth: May 1, 1969  
Citizenship: Canadian  
Rank: Professor

## II. Academic Record:

Post-doctoral fellowship in Health Economics (Oct 2000-June 2001)  
University of Calgary

Masters in Health Economics (August, 1999 – Oct 2000)  
University of York, England

Nephrology fellowship (July, 1997 - June 1999)  
University of Calgary

- Fellow of the Royal College of Physicians and Surgeons of Canada, Nephrology (September 2000)

General Internal Medicine Residency (July, 1994 - June 1997)  
University of Calgary

- Fellow of the Royal College of Physicians and Surgeons of Canada, Internal Medicine (June 1998)

Doctor of Medicine (May 1994)  
University of Toronto

- Honours Standing

Bachelor of Science (May, 1990)  
University of Saskatchewan

- Honours Degree in Biochemistry

**Research Experience:**July, 1999 – June, 2001:      **Research fellow***A cost-utility analysis of renal replacement therapy: Accounting for casemix*

- Supervisor: Dr. C. Donaldson, Univ. of Calgary
- Salary support through a combined Kidney Foundation of Canada / Alberta Heritage Foundation for Medical Research fellowship

July, 1999 – Sept, 2000:      **Masters in Health Economics***An economic evaluation of hemodialyser reuse vs conventional single- use hemodialysis*

- University of York, England
- Salary support through a combined Kidney Foundation of Canada / Alberta Heritage Foundation for Medical Research fellowship

July, 1997 – June, 1999:      **Nephrology Fellowship research projects***Hyperhomocysteinemia, vascular access thrombosis and the risk for atherosclerotic vascular disease in patients with end-stage renal disease*

- Supervisor: Dr N. Scott-Douglas, Univ. of Calgary
- Designed and conducted two cross-sectional analyses which demonstrated a strong association between hyperhomocysteinemia and atherosclerosis in patients with renal failure
- two publications in peer reviewed journals (See publications 5,6)

*The effects of vitamin B12, folic acid, and serine supplementation on homocysteine levels in patients with end-stage renal failure on dialysis*

- Supervisor: Dr N. Scott-Douglas
- Designed and conducted this randomized trial which enrolled 82 patients
- Two publications (See peer-reviewed publications)

1994-96:      **Medical Resident Research Project***Antituberculous drug resistance in Alberta's immigrants with tuberculosis*

- Supervisor: Dr R. Cowie
- Dept of Respiratory Medicine, Univ. of Calgary
- publication in peer-reviewed journal

### III. Awards and Distinctions

#### *2015 University of Calgary Killam Annual Professor Award*

- Awarded in recognition of research and teaching excellence, as well as service to the University and Community
- University of Calgary

#### *Svare Professorship in Health Economics – awarded 2014*

- Endowed Chair in Health Economics
- Faculty of Medicine, University of Calgary

#### *2012 Watanabe Distinguished Achievement Award for Overall Excellence*

- Faculty of Medicine, University of Calgary

#### *2012 CIHR-CMAJ Top Achievements in Health Research Awards*

- CIHR-CMAJ
- Co-winner with Dr Hemmelgarn / Tonelli

#### *2012 President's Excellent Award for Outstanding Achievement in Research*

- Alberta Health Services
- Co-winner with Dr Hemmelgarn / Tonelli

#### *2011 Dean's Publication and Mentorship Prize winners*

- Faculty of Medicine, University of Calgary
- Awarded for Mentorship and Publication Excellence by a graduate student (Dr Steve Heitman) for publication in PLOS, Colorectal Cancer Screening for Average-Risk North Americans: An Economic Evaluation

#### *Letter of Excellence Teaching Award (2010)*

- Faculty of Medicine, University of Calgary
- Awarded for Teaching in Undergraduate Medical Education

#### *Cochrane Distinguished Achievement Award (2010)*

- Faculty of Medicine, University of Calgary
- Awarded to one researcher in the Faculty of Medicine for Excellence in Research, 2010 Academic Year

#### *Alberta Innovates – Health Solutions (formerly AHFMR) Health Scholar Award (2010-17)*

- Based on grant entitled “Determining the effectiveness and cost-effectiveness of chronic disease management programs for patients with diabetes”
- Alberta Innovates – Health Solutions
- \$100,000 per year plus fringe benefits Salary Award

#### *Cochrane Distinguished Achievement Award (2003)*

- Faculty of Medicine, University of Calgary
- Awarded to one researcher in the Faculty of Medicine for Excellence in Research, 2003 Academic Year

*CIHR New Investigator Award (2003-2008)*

- Based on grant entitled “Early vs deferred-start dialysis: An Economic Evaluation of a Dialysis Outcomes Quality Initiative (DOQI) Guideline”
- Canadian Institutes of Health Research
- \$50,000 per year plus fringe benefits Salary Award
- Temporary leave granted Jan 1, 2007 – July 1, 2008 during initial tenure as Chair of Canadian Expert Drug Advisory Committee (as such, Salary award extended by to January 1, 2010)

*Research Fellowship Award*

July 1999 – June 2001:

- Jointly funded by *Kidney Foundation of Canada* and *Alberta Heritage Foundation for Medical Research*
- Salary support for two year research program in Health Economics

*“Proud to Support Excellence Kidney Foundation of Canada” Researcher*

September 2000:

- Kidney Foundation of Canada
- featured as a researcher in the 2000 issue of Proud to Support Excellence

*Internal Medicine Residency, University of Calgary*

Sept. 1995: Univ. of Calgary's representative to the Canadian Resident-Fellow Competition in Respiratory Research

- St. Sauveur, Quebec

*Medicine, University of Toronto:*

1993-94: The Chappell Prize in Clinical Medicine

- awarded to the best student in Clinical Medicine during final year of medical training

1993-94: The Issei Scholarship in Medicine and Surgery

- awarded for academic excellence in Internal Medicine and Surgery in final year of medical training

1993-94: Medical Society Honour Award

- awarded for outstanding contribution to the Faculty of Medicine during the undergraduate years

1990-94: William Edward Corlett Memorial Scholarship

- awarded for high academic standing in premedical training

1990-94: Dr C.S. Wainwright Memorial Scholarship

- awarded annually for high academic standing

1993: Appointed to Alpha Omega Alpha Honor Medical Society

- awarded to students performing in the top 25 % of the class academically during years I-III

1993: Medical Athletics Letter

1992: Summer Scholarship from Univ. of Toronto, Faculty of Medicine

*Biochemistry, University of Saskatchewan:*

1986-90: Undergraduate Honours Scholarship

- 1988: Dorothy Kline Memorial Award
- awarded for excellence in Biochemistry
- 1988: Department of Chemistry Book Prize
- awarded for excellence in Organic Chemistry

#### **IV. Academic Appointments**

Professor (2012 - )

Departments: Medicine (Division of Nephrology) and Community Health Sciences,  
University of Calgary

Svare Professorship in Health Economics (2014-2019)

Faculty of Medicine

University of Calgary

Scientific Director (2014 – 2016)

Alberta Health Services Kidney - Strategic Clinical Network

President (2014-2016)

Canadian Society of Nephrology

Other affiliations:

Alberta Innovates – Health Solutions Health Scholar

Associate Editor, cJASN (2011-2013)

#### **V. Educational Activities:**

Post-graduate courses:

*MDSC 643.01: Biostatistics I*

- This course focused on classical statistical methods for the analysis of data in community health
- The Department of Community Sciences, Univ. of Calgary

*MDSC 643.02: Biostatistics II*

- This course focused on model-based statistical methods for the analysis of data in community health.
- The Department of Community Sciences, Univ. of Calgary

Other courses:

*The Evidence for Evidence: Getting value for money in health care*

- The Institute of Health Economics in Edmonton, Alberta (April, 1999)

*An Education Program for Clinicians in the Techniques of Economic Evaluation of Health Care Interventions*

- The Institute of Pharmaco-Economics in Edmonton, Alberta (Jan, 1998)

*Clinical trials course, level I and II* - a week long course on clinical trial methodology during which each student developed a randomized clinical trial

- The Department of Community Sciences, Univ. of Calgary

## Teaching experience

### Courses:

- 2003-present: Course coordinator for MDCH 663, a graduate course in “Decision Analysis in Health Care Economic Evaluation”
- Community Health Sciences graduate level course
  - Half-term course
- Jan – June 2002: Course co-coordinator and teacher of MDSC 755.35, a Readings Course on “Economic evaluation in health care”, along with Dr. C. Donaldson
- Community Health Sciences MSc level course
  - Half-term course
- 2001 – present Preceptor for Renal course, 1<sup>st</sup> year medical students
- University of Calgary medical school
  - approximately 20 hours contact time per year
- 2001-present Preceptor for final year medical student clinical skills teaching
- University of Calgary medical school
  - Approximately 40 hours contact time per year
- 1996–1999: Preceptor for 1<sup>st</sup> and 2<sup>nd</sup> year medical students’ *Clinical Skills* courses
- University of Calgary medical school
  - Approximately 30 hours contact time per year
- 1997-1999: Preceptor for 2<sup>nd</sup> year medical students’ Nephrology Clinical Correlates courses and small group tutorials
- University of Calgary medical school
  - Approximately 10 hours contact time per year

## Graduate Students Supervised:

Mischa Kowall

- 2001-2002, MSc, Department of Economics, University of Calgary
- *An economic evaluation of continuous renal replacement therapy and intermittent hemodialysis for the treatment of acute renal failure*

Helen Lee

- 2001-2002, MEc, Department of Economics, University of Calgary
- *An economic evaluation of activated protein C in severe sepsis*

Dr. Caren Wu

- 2002-2005, MSc, Department of Community Health Sciences, University of Calgary
- *Cost effectiveness of Accelerated Management of Transient Ischemic Attack Compared to Standard care*

Dr. Carmen Brauer

- 2002-2003, MSc, Department of Health Economics, York University, England
- *An economic evaluation of operative versus non-operative treatment of displaced intra-articular calcaneal fractures*

Dr. Brendan Murphy

- 2002-2003, MSc, Department of Community Health Sciences, University of Calgary
- *Identification of the important determinants of successful development of native arteriovenous fistulae in a prospective cohort of incident ESRD patients*

Fiona Shrive

- 2002-2006, PhD, Department of Community Health Sciences, University of Calgary
- *An economic evaluation of drug-eluting stents in the management of patients with coronary artery disease*

Song Gao

- 2003-2005, MSc, Department of Community Health Sciences, University of Calgary
- Chronic Kidney Disease Among First Nations people in Southern Alberta: Access and Barriers to Appropriate Care

Mike Walsh

- 2006-2009, MSc, Department of Community Health Sciences, University of Calgary
- Investigating the validity of surrogate endpoints used in clinical trials of renal vasculitis
- Funded AI-HS / Kidney Foundation of Canada

Luc Berthiaume

- 2005-2009, MSc, Department of Community Health Sciences, University of Calgary
- The cost effectiveness of tight glyceemic control in the general intensive care unit

Steve Heitman

- 2007-2011, MSc, Health Economics, York University
- The impact of including indirect costs on the cost effectiveness of screening for colorectal cancer
- Funded AI-HS / CAGS / CIHR

**Fiona Shrive**

- 2006-2007, Post Doctoral Fellow, Department of Community Health Sciences, University of Calgary
- The cost effectiveness and economic implications of increasing coronary catheterization rates
- Funded AI-HS / CIHR

**Wenjie Wang**

- 2006-2007, Post Doctoral Fellow, Department of Medicine, University of Calgary
- The impact of increasing dialysis adequacy on quality of life

**Lauren Bresie**

- 2010-12, Post Doctoral Fellow, Department of Community Health Sciences, University of Calgary
- The impact of safety warnings on prescribing of oral hypoglycemic agents in diabetes
- Funded CIHR

**Kerry McBrien**

- 2010-13, Post Doctoral Fellow, Department of Community Health Sciences, University of Calgary
- The cost effectiveness of intensive blood pressure lowering in diabetes
- Funded AI-HS

**Janelle Seah**

- 2010, Master's Health Econ, York University
- The cost and cost effectiveness of chronic disease management programs in diabetes

**Erika Penz**

- 2011-2013, MSc, Health Economics, York University
- The cost-effectiveness of pleural catheters in patients with malignant pleural effusion
- Funded AI-HS

**Lianne Barnieh**

- 2010-13, Post Doctoral Fellow, Department of Community Health Sciences, University of Calgary
- The cost effectiveness incentives to increase the use of living related kidney transplantation
- Funded AI-HS

**Bikaramjit Mann**

- 2011-15, Medical Resident, University of Calgary Internal Medicine Program  
Department of Community Health Sciences, University of Calgary
- The impact of cost-sharing on patients outcome in chronic disease



David Campbell

- 2012-2016, Graduate Student (PhD), Department of Community Health Sciences, University of Calgary
- The impact of financial barriers on care and outcomes for patients with chronic disease
- Funded AI-HS

Jenine Leal

- 2014-2018, Graduate Student (PhD), Department of Community Health Sciences, University of Calgary
- The cost-effectiveness of strategies to reduce clostridium difficile
- Funded Eyes High Program

Erik Venos

- 2014-2016, Graduate Student (Master's), Department of Community Health Sciences, University of Calgary
- The cost and clinical implications of the Choosing Wisely Campaign in diabetes

## VI. Administrative Responsibilities

### i. Departmental

**Member:** Search and selection committee – Head, Community Health Sciences (2013-14)

**Member:** Academic Relationship Plan Management committee (2012-present)

**Member:** Division of Nephrology Research review committee (2009 - present)

**Member:** Search and selection committee – Head, Division of General Internal Medicine (2010)

**Member:** graduate student supervisory committees within Community Health Sciences

**Co-Chair:** Department of Medicine; Division of Nephrology Innovation Program (2007-2010)

developing and overseeing the establishment of Nephrology central triage and urgent evaluation clinics

developing and overseeing the establishment of group-based dialysis modality education to increase the use of home-based dialysis (based on the results of our successful randomized trial testing the effectiveness of the group education format).

### ii. Regional Health Authority

Calgary Health Region Pharmacy and Therapeutics committee (2001 to 2004)

### iii. Provincial / National

**Member:** Expert Committee on Drug Evaluation and Therapeutics, an 8-member Committee which makes recommendations to the Alberta Minister of Health as to whether to add new pharmaceutical products to the Alberta Health and Wellness Drug Benefit List based on clinical and cost-effectiveness criteria (Member, January 2002 – 2006 (**Ministerial appointment**))

**Member:** Canadian Expert Drug Advisory Committee (2003-2006), an 11 member Committee that makes recommendations as to whether to add new pharmaceutical products to each of the provincial drug insurance plans based on clinical and cost-effectiveness criteria

**Chair:** Canadian Expert Drug Advisory Committee (2006-2008)

## VII. Professional Activities

### *Associate Editor*

cJASN 2011 - 2014

### *Journal Reviews*

Canadian Medical Association Journal	2002 - present
Kidney International	2001 - present
The Canadian Journal of Gastroenterology	2001 - present
Journal of the American Society of Nephrology	2002 - present
American Journal of Kidney Diseases	2002 - present
Nephrology, Dialysis, Transplantation	2002 - present
New England Journal of Medicine	2003 - present
Critical Care Medicine	2003 - present
Pharmacoeconomics	2003 - present
JAMA	2003 - present
Clinical Nephrology	2003 - present
Social Science and Medicine	2007 - present

### *Committees*

Reformulary Drug Expert Committee

- **Member**
- Makes Drug listing recommendation to Private Drug insurance companies
- 2011-2012

Canadian Society of Nephrology Scientific Committee

- **Chair**
- Mandate is to enhance and promote Nephrology Research in Canada
- 2004 - 2012

Canadian Society of Nephrology Mineral Metabolism Guidelines Committee

- **Chair**
- Commentary released 2010

Canadian Society of Nephrology Anemia Guidelines Committee

- **Chair**
- Updated Guidelines released 2008

Canadian Expert Drug Advisory Committee

- Canadian Agency for Drugs and Technologies in Health
- 11 member Committee that makes recommendations as to whether to add new pharmaceutical products to each of the provincial drug insurance plans based on clinical and cost-effectiveness criteria
- **Chair**, October 2006 – Dec 31, 2008
- **Member**, September 2003 - 2006

Expert Committee on Drug Evaluation and Therapeutics

- Alberta Health and Wellness
- 8-member Committee makes recommendations to the Alberta Minister of Health as to whether to add new pharmaceutical products to the Alberta Health and Wellness Drug Benefit List based on clinical and cost-effectiveness criteria
- **Member**, January 2002 – 2006 (**Ministerial appointment**)

Sub-Committee for the Review of Benefit Status of Products and Categories on the Alberta Health and Wellness Drug Benefit List

- Subcommittee of the Expert Committee on Drug Evaluation and Therapeutics
- **Member**, 2002 – 2004

Pharmacy and Therapeutics committee:

- Calgary Health Region
- Committee determines whether to add new pharmaceutical products to the Calgary Health Region formulary
- **Member**, 2001 – 2005

**Member**, Scientific Committee, Division of Nephrology Research Group

- I helped establish the University of Calgary Nephrology Research Group and now am on the Scientific Review Committee

**Grant Review Committees:**

1. **Member** and Internal Reviewer for CIHR Committee: “Team Planning and Development Grants – Developing New Research Teams to Enhance Quality of life”
  - January, 2004
2. **Member** and Internal Reviewer for the KRESCENT program
  - March 2005- 2007
3. CIHR Salary Award **Member** and Internal Reviewer
  - 2009 - 2013
4. **Member**, AI-HS Clinical Fellowship Award Review Committee
  - 2011
5. **Chair**, AI-HS Clinical Fellowship Award Review Committee
  - 2012 - 2015

## VIII. Research Support:

### A) As principal investigator or co-principal investigator:

1) *Hyperhomocysteinemia and the Risk for Atherosclerotic Vascular Disease in Patients with End-Stage Renal Disease and Hyperhomocysteinemia, Anticardiolipin Antibody Status and the Risk for Vascular Access Thrombosis in Patients with ESRD on Hemodialysis.*

Proposal author: BJ Manns\*  
Principal investigator: NW Scott-Douglas\*  
Co-investigators: ED Burgess, HG Parsons, JP Schaefer, ME Hyndman,  
Funding: \$12,000.00  
Funding Sources:

- Endowment Awards, Faculty of Medicine, Univ. of Calgary  
\$11,000.00
- Centre for the Advancement of Health, Calgary  
\$1000.00

Years: 1996-1999

2) *The effects of vitamin B12, folic acid, and serine supplementation on homocysteine levels in patients with end-stage renal failure on dialysis.*

Proposal author: BJ Manns\*  
Principal investigator: NW Scott-Douglas\*  
Co-investigators: E. Burgess, HG Parsons, JP Schaefer, ME Hyndman, F Snyder, P Bridge  
Funding: \$60,000.00  
Funding Sources:

- Kidney Foundation of Canada  
\$40,000.00
- Special Funding Competition, Centre for the Advancement of Health  
\$20,000.00

Years: 1998- 2000

3) *A Cost-Utility Analysis of Renal Replacement Therapy: Accounting for casemix.*

Proposal author: BJ Manns\*\*  
Principal investigator: C. Donaldson\*\*  
Co-investigators: K. Taub, W. Ghali  
Funding:

1999	\$20,000.00
2000	\$45,660.30
2001	\$45,660.30

Funding Sources:

1999	Centre for the Advancement of Health, Calgary
2000	Health Research Fund, Alberta Heritage Foundation for Medical Research
2001	Health Research Fund, Alberta Heritage Foundation for Medical Research

Years: 1999-2001

- 4) *An Economic Evaluation of Improving Dialysis Adequacy in Large Hemodialysis Patients*  
Proposal author: BJ Manns  
Principal investigator: BJ Manns  
Co-investigators: K. Taub, J. Johnson, C. Donaldson  
Funding: 2001 \$46,650.00  
 2002 \$46,650.00  
Funding Sources: Kidney Foundation of Canada  
Years: 2001-2003
- 5) *Recombinant Human Activated Protein C for Severe Sepsis in the Intensive Care Unit: A clinical decision analysis*  
Proposal author: B. Manns  
Principal Investigator: B. Manns  
Coinvestigators: C. Doig, C. Donaldson  
Funding: \$30,883  
Funding sources: Institute of Health Economics, Alberta  
Years: 2002
- 6) *Early vs deferred-start dialysis: An Economic Evaluation of a Dialysis Outcomes Quality Initiative (DOQI) Guideline*  
Proposal author: B. Manns  
Principal Investigator: B. Manns  
Coinvestigators: K. Taub, W. Ghali, J. Johnson  
Funding: Salary support award; \$50,000 per year plus fringe benefits  
Funding sources: **CIHR New Investigator Salary Award**  
Years: 2003-2008
- 7) *Cost effectiveness of Accelerated Management of Transient Ischemic Attack Compared to Standard care*  
Proposal author: C. Wu  
Principal Investigator: B. Manns  
Coinvestigators: A. Buchan, C. Donaldson  
Funding: 2003 \$24,900  
Funding sources: Calgary Health Region Annual R&D Funding Competition  
Years: 2003-2004
- 8) *Analysis of the Determinants of Incident Year Costs in End-Stage Renal Disease*  
Proposal author: S. Klarenbach and B. Manns  
Principal Investigator: B. Manns  
Coinvestigators: P. Jacobs, M. Tonelli  
Funding: 2003 \$23,000  
Funding sources: Health Research Fund, Alberta Heritage Foundation for Medical Research and Calgary Health Region  
Years: 2003-2004

9) ***Establishment and maintenance of a vascular access in incident hemodialysis patients: A prospective cost analysis***

Proposal author: B. Manns  
Principal Investigator: B. Manns  
Coinvestigators: M. Tonelli, S. Yilmaz, B. Murphy, V. Radkevich  
Funding: 2003 \$4,992  
Funding sources: Center for Advancement of Health, Calgary Health Region  
Years: 2003-2004

10) ***Eliciting preferences for new interventions: A comparison of decision-makers and the public with regards to priority setting***

Proposal author: B. Manns  
Principal Investigator: B. Manns  
Coinvestigators: G. Currie, M. vanderPol  
Funding: 2003 \$9,950  
Funding sources: Institute of Health Economics, Alberta  
Years: 2003-2004

11) ***Eliciting the public's preferences for priority setting for new pharmaceuticals***

Proposal author: B. Manns  
Principal Investigator: B. Manns, G. Currie, M. van der Pol  
Co-investigators: M. Ryan  
Funding: \$30,249  
Funding sources: Institute of Health Economics, Alberta  
Years: 2004-2005

12) ***Optimizing Prevention of Vascular Disease in Alberta: A program of health outcomes research***

Principal Investigator: F. McAlister  
Co-Principal Investigators: B. Manns, J. Johnson, R. Tsuyuki, S. Majumdar  
Funding: \$870,000  
Funding source: Programs of Health Research Competition  
 Alberta Heritage Foundation for Medical Research  
Years: 2004-2007

13) ***Nocturnal Hemodialysis Versus Conventional Three Times Per Week Hemodialysis: A Randomized Clinical Trial***

Principal Investigator: B. Manns, B. Culleton  
Co-investigators: M. Tonelli, S. Klarenbach  
Funding: \$100,000  
Funding source: Kidney Foundation of Canada  
Years: 2004-2006

- 14) ***Evaluating the impact of a restricted reimbursement policy for selected antimicrobial agents on utilization of targeted antibiotics, clinical outcomes, and costs***  
 Principal Investigator: B. Manns  
 Co-investigators: B. Hemmelgarn, K. Laupland, C. Mitchell  
 Funding: \$47,000  
 Funding source: IHE  
 Years: 2005-2007
- 15) ***Drug eluting stents for coronary heart disease: A systematic review and economic evaluation***  
 Co-Principal Investigators: B. Manns, W. Ghali  
 Co-investigators: M. Knudtson  
 Funding: \$60,000  
 Funding Source: APPROACH  
 Years: 2003-2005
- 16) ***Economic evaluation of capsule endoscopy for obscure gastrointestinal bleeding***  
 Co-Principal Investigators: B. Manns, R. Hilsden  
 Co-investigators: S. Heitman, R. Pannacione  
 Funding: \$100,000  
 Funding source: AHFMR Health Research Fund  
 Years: 2005-2007
- 17) ***Modeling Chronic Kidney Disease: Optimal Modeling Methods & Implications for Screening Programs for CKD***  
 Co-Principal Investigators: B. Manns, S. Klarenbach  
 Co-investigators: B. Hemmelgarn, B. Culleton  
 Funding: \$100,000  
 Funding source: AHFMR  
 Years: 2006-2008
- 18) ***Sevelamer for patients with end-stage renal disease: A systematic review and economic evaluation***  
 Principal Investigator: B. Manns  
 Co-investigators: M. Tonelli, S. Klarenbach, B. Culleton  
 Funding: \$50,000  
 Funding Source: Canadian Agency for Drugs and Technologies in Health  
 Years: 2005-2006
- 19) ***A randomized controlled trial evaluating the effects of long-term, low-dose corticosteroid therapy compared to placebo on renal flare rates in during maintenance therapy for proliferative lupus nephritis: a pilot study***  
 Principal Investigator: B. Manns  
 Co-investigators: B. Hemmelgarn, M. Walsh, PJ Devereaux, D. Jayne  
 Funding: \$10,000  
 Funding Source: Center for Advancement of Health  
 Years: 2005-2007



- 20) ***The impact of using surrogate endpoints on economic evaluations***  
 Principal Investigator: B. Manns  
 Co-investigators: F. Shrive  
 Funding: \$70,000  
 Funding Source: CADTH  
 Years: 2007-2009
- 21) ***An economic evaluation of colorectal cancer screening options***  
 Principal Investigator: B. Manns  
 Co-investigators: S. Heitman, R. Hilsden  
 Funding: \$50,000  
 Funding Source: Canadian Agency for Drugs and Technologies in Health  
 Years: 2008-2009
- 22) ***An economic evaluation of Nocturnal Hemodialysis***  
 Principal Investigator: B. Manns  
 Co-investigators: S. Klarenbach  
 Funding: \$100,000  
 Funding Source: CIHR  
 Years: 2008-2010
- 23) ***A systematic review and economic evaluation of statin use in primary prevention***  
 Co-Principal Investigators: B. Manns and M. Tonelli  
 Co-investigators: B. Hemmelgarn, S. Klarenbach  
 Funding: \$110,000  
 Funding Source: CADTH  
 Years: 2009-2010
- 24) ***Improving the Efficient and Equitable Care of Patients with Chronic Medical Conditions Interdisciplinary Chronic Disease Collaboration (ICDC)***  
 Co-Team Leaders: Hemmelgarn, Manns, Tonelli  
 Funding: \$5,000,000  
 Funding Source: AHFMR 2008 Team Grant Competition  
 Years: 2009-2014
- 25) ***AHFMR Scholar Salary Award for grant entitled: “Determining the effectiveness and cost-effectiveness of chronic disease management programs for patients with diabetes”***  
 Funding: \$700,000  
 Funding Source: Alberta Innovates – Health Solutions  
 Years: 2010-2017
- 26) ***Coronary angiography and revascularization for patients with Stage 4 and 5 non-dialysis chronic kidney disease: A decision analysis***  
 Co-Principal Investigators: B. Manns, M. James  
 Co-investigators: Hemmelgarn, Tonelli  
 Funding: \$74,876  
 Funding Source: CIHR  
 Years: 2010-2011

- 27) *A systematic review of drug use optimization and cost-containment measures adopted within the OECD nations*  
 Co-Principal Investigators: F. Clement (nominated PI), B. Manns  
 Co-investigators: L. Jardine  
 Funding: \$100,000  
 Funding Source: CIHR  
 Years: 2012-2013
- 28) *The Impact of Reduced ICU Bed Availability Due to the H1N1 Pandemic on the Care and Outcomes of Acutely Unwell Hospitalized Patients*  
 Co-Principal Investigators: B. Manns, T. Stelfox,  
 Co-investigators: C. Doig, B. Hemmelgarn, S. Bagshaw  
 Funding: \$92,600  
 Funding Source: CIHR  
 Years: 2010-2011
- 29) *The impact of primary care networks on the care and outcomes of patients with diabetes*  
 Co-Principal Investigators: B. Manns, M. Tonelli, B. Hemmelgarn  
 Co-investigators: F. Clement, K. McBrien, P. Sargious, J. Johnson,  
 A. Laupacis  
 Funding: \$256,226  
 Funding Source: CIHR  
 Years: 2011-2013
- 30) *Assessing the acceptability of financial incentives to kidney donation*  
 Principal Investigator: B. Manns  
 Co-investigators: S. Klarenbach  
 Funding: \$25,000  
 Funding Source: Goldlist Foundation  
 Years: 2011-2013
- 31) *The CANadian KidNey KNowledge Translation and Generation NETwork (CANN-NET)*  
 Principal Investigator: B. Manns  
 Co-investigators: M. Evans, L. Maccallum, F. Madore, M. Tonelli, R. Wald,  
 B. Hemmelgarn, M. Walsh, M. Zappitelli  
 Funding: \$720,000  
 Funding Source: CIHR - Network Catalyst - Diabetes, Obesity, Digestive  
 and Kidney  
 Years: 2011-2014
- 32) *Translating evidence to improvements in care and outcomes for people with diabetes*  
 Principal Investigator: B. Manns  
 Co-investigators: A. Edwards, P. Sargious, G. Allan, T. Braun, J. Grimshaw,  
 B. Hemmelgarn, N. Ivers, J. Johnson, S. Long, S Straus  
 K. McBrien, C. Naugler, M. Tonelli, A. Tricco, C Yu.  
 Funding: \$24,995  
 Funding Source: CIHR – Planning Grant  
 Years: 2012-2013

- 33) *Patient navigators and living kidney donor transplantation***  
 Principal Investigator: B. Manns  
 Co-investigators: S. Klarenbach  
 Funding: \$15,000  
 Funding Source: Goldlist Foundation  
 Years: 2013-2014
- 34) *The Interdisciplinary Chronic Disease Collaboration (ICDC) Team***  
 Co-Team Leaders: Hemmelgarn, Manns, Tonelli  
 Funding: \$5,000,000  
 Funding Source: AHFMR 2013/14 Team Grant Competition  
 Years: 2014-2019
- 35) *Screening for Chronic Kidney Disease – the SEEKD study***  
 Co-PIs: Manns, Hemmelgarn  
 Funding: \$90,000  
 Funding Source: Kidney Foundation of Canada  
 Years: 2014-2015
- 36) *The Access Study***  
 Principal Investigator: Manns  
 Funding: \$1,450,000  
 Funding Source: Alberta Health  
 Years: 2014-2017
- 37) *Canadian Innovative Methods involving Patients and Researchers in Outcome Improvements for Chronic Kidney Disease (Can-IMPROVE CKD): a strategic planning meeting***  
 Principal Investigator: Manns  
 Funding: \$20,000  
 Funding Source: CIHR  
 Years: 2015
- 38) *Listening, Learning and Leading: Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD)***  
 Co-Principal Investigator: Levin, Manns  
 Funding: \$50,000  
 Funding Source: CIHR SPOR letter of intent  
 Years: 2015

**B) As co-investigator:****1) *Impact of multiple organ dysfunction syndrome in the intensive care unit on quality of life and costs***

Proposal author: C. Doig  
Principal Investigator: C. Doig  
Coinvestigators: B. Manns, D. Sandham, C. Eagle, G. Fick, C. Donaldson, W. Ghali, L. Sutherland.  
Funding: 2001 \$50,000  
 2002 \$50,000  
Funding sources: Health Research Fund, Alberta Heritage Foundation for Medical Research  
Years: 2001-2003

**2) *The effect of continuous positive airway pressure on health resource utilization among patients with obstructive sleep apnea: A multi-dimensional analysis***

Proposal author: S. Heitman  
Principal Investigator: W. Tsai  
Coinvestigators: B. Manns, W. Flemons, W. Ghali  
Funding: 2002 \$50,000  
 2003 \$50,000  
Funding sources: Health Research Fund, Alberta Heritage Foundation for Medical Research and Calgary Health Region  
Years: 2001-2003

**3) *A Computerized Chronic Kidney Disease Network: A Database for Accessing Care and Determining Progression***

Proposal author: K. Taub, B. Manns, B. Culleton and B. Hemmelgarn  
Principal Investigator: K. Taub  
Coinvestigators: B. Manns, B. Culleton, B. Hemmelgarn, K. McLaughlin  
Funding: 2003-2006 \$480,000 total  
Funding sources: Amgen Canada  
Years: 2003-2006

**4) *Progression of CKD in the Elderly***

Principal Investigator: B. Hemmelgarn  
Co- Investigators: B. Manns, B. Culleton, M. Tonelli, K. Taub  
Funding: \$100,000  
Funding source: Health Research Fund  
 Alberta Heritage Foundation for Medical Research  
Years: 2004-2006

**5) *Societal costs of colorectal cancer screening in Alberta***

Principal Investigator: R. Hilsden  
Co-investigators: B. Manns, S. Heitman, C. Mitchell  
Funding: \$129,755  
Funding source: AHFMR Health Research Fund  
Years: 2005-2007

- 6) ***Progression and management of chronic kidney disease among First Nations People***  
 Principal Investigator: B. Hemmelgarn  
 Co-investigators: B. Manns, M. Tonelli, S. Ahmed, W. Ghali  
 Funding: \$184,000  
 Funding Source: CIHR  
 Years: 2008-2010
- 7) ***A systematic review and economic evaluation of continuous renal replacement therapy in patients with acute renal failure***  
 Principal Investigator: M. Tonelli  
 Co-investigators: B. Manns, R. Padwal, S. Klarenbach  
 Funding: \$96,025  
 Funding Source: Canadian Agencies for Drugs and Technologies in Health  
 Years: 2006
- 8) ***Hematopoietic hormones in the treatment of anemia related to cancer***  
 Principal Investigator: M. Tonelli  
 Co-investigators: B. Manns, S. Klarenbach  
 Funding: \$115,282  
 Funding Source: Canadian Agencies for Drugs and Technologies in Health  
 Years: 2007
- 9) ***A systematic review and economic evaluation of hematopoietic therapies in patients with chronic renal failure***  
 Principal Investigator: M. Tonelli  
 Co-investigators: B. Manns, S. Klarenbach  
 Funding: \$119,525  
 Funding Source: Canadian Agencies for Drugs and Technologies in Health  
 Years: 2007
- 10) ***Bariatric surgery for severe obesity***  
 Principal Investigator: M. Tonelli  
 Co-investigators: B. Manns, R. Padwal, S. Klarenbach  
 Funding: \$140,760  
 Funding Source: Canadian Agencies for Drugs and Technologies in Health  
 Years: 2009
- 11) ***Access to Kidney Transplantation in British Columbia and Alberta***  
Principal investigator: J. Gill  
Co-Investigators: M. Tonelli, S. Gourishankar, B. Manns, K. McLaughlin.  
Funding: 129,000  
Funding sources: CIHR  
Years: 2005-2010

- 12) ***Trace element status in chronic hemodialysis patients***  
Principal investigator: M. Tonelli  
Co-Investigators: B. Culleton, S. Klarenbach, B. Hemmelgarn, B. Manns, K. Jindal, C. Field, G. Cembrowski, D. Holmes, N. Wiebe, K. Oseen, J. Gill  
Funding: \$992,811  
Funding sources: CIHR  
Years: 2007-2012
- 13) ***Validation of a coding algorithm to define chronic kidney disease using admin data***  
Principal investigator: B Hemmelgarn  
Co-Investigators: H Quan, B Manns, M Tonelli  
Funding: \$96,725/year x 1 years  
Funding sources: Public Health Agency of Canada  
Years: 2008 - 2009
- 14) ***Progression and management of chronic kidney disease among First Nations People***  
Principal investigator: B Hemmelgarn  
Co-Investigators: S Ahmed, L Crowshoe, P Faris, W Ghali, B Manns, M Tonelli  
Funding: \$79,421/year x 2 years  
Funding sources: CIHR  
Years: 2008 - 2010
- 15) ***A cost-effectiveness study of exercise-based Cardiac Rehabilitation***  
Principal Investigators: F. Clement  
Co-investigator: B. Manns, W. Ghali, T. Hauer, J. Stone, S. Aggarwal, M. Knudtson, C. Norris  
Funding \$100,000  
Funding Source M.S.I Foundation  
Years 2011-2013
- 16) ***A Systematic Review of Drug Use Optimization and Cost-Containment Measures Adopted Within the OECD Nations***  
Principal Investigators: F. Clement  
Co-investigators: B. Manns  
Funding \$18,000  
Funding Source University of Calgary Grant Committee Seed Grant  
Years 2011-2012
- 17) ***Improving risk prediction in older adults using eGFR and proteinuria***  
Principal Investigator: B Hemmelgarn  
Team members: F Clement, M James, B Manns, R Quinn, P Ravani, M Tonelli  
Funding: \$166,448 over 2 years (\$83,224 per year)  
Funding sources: CIHR  
Years: 2011 – 2013

- 18) ***Complications of arteriovenous fistulas, arteriovenous grafts and tunneled cuffed catheters for hemodialysis: Risk patterns, comparability and impact on patient outcomes***  
Principal Investigator: P Ravani  
Team members: B Hemmelgarn, M James, B Manns, R Quinn, P Ravani, M Tonelli  
Funding: \$130,000 over 2 years (\$65,000 per year)  
Funding sources: CIHR  
Years: 2011 – 2013
- 19) ***The BK: KIDNI Trial (BK:Kinase inhibition to decrease nephropathy intervention trial)***  
Co-Principal Investigators: LA Tibbles, B Hemmelgarn  
Team members: P Ravani, B Manns,  
Funding: \$3,319,686 over 4 years  
Funding sources: CIHR  
Years: 2009 - 2013
- 20) ***Access to and quality of cardiac care for First Nations***  
Principal investigator: B Hemmelgarn  
Co-Investigators: S Ahmed, W Ghali, M Knudtson, M Tonelli, B Manns, P Faris, H Quan.  
Funding: \$215,875 over 3 years  
Funding sources: CIHR  
Years: 2009 – 2012
- 21) ***Role of residence location in the care of elderly Canadians with kidney failure***  
Principal investigator: M Tonelli  
Co-Investigators: S Davison, J Gill, B Hemmelgarn, S Klarenbach, B Manns, N Pannu, N Wiebe, K Yeates  
Funding: \$130,476/year x 5 years  
Funding sources: CIHR  
Years: 2008 - 2013
- 22) ***Influence of deficiency and excess of trace elements on outcomes in HD patients***  
Principal investigator: M Tonelli  
Co-Investigators: B Hemmelgarn, G Cembrowski, B Culleton, C Field, J Gill, K Jindal, S Klarenbach, B Manns, N Wiebe  
Funding: \$996,000  
Funding sources: CIHR  
Years: 2007 - 2012

- 23) ***Chronic kidney disease among First Nations people in Alberta: Prevalence, progression and access to care***  
Principal investigator: B Hemmelgarn  
Co-Investigators: B Manns, B Culleton, M Tonelli, L Crowshoe, L Svenson, WA Ghali, S Bertazzon,  
Funding: \$210,000  
Funding sources: CIHR  
Years: 2005 - 2008
- 24) ***The role of place and relocation in the care of Canadians with end-stage renal disease***  
Principal investigator: M Tonelli  
Co-Investigators: B Manns, B Culleton, B Hemmelgarn, J Gill,  
Funding: \$180,000  
Funding sources: CIHR  
Years: 2005 – 2008
- 25) ***Chronic kidney disease among the elderly in Alberta: Prevalence and access to care***  
Principal investigator: B Hemmelgarn  
Co-investigators: B Manns, B Culleton, M Tonelli, S Bertazzon  
K Taub, M Visser  
Funding: \$98,572  
Funding sources: AHFMR  
Years: 2004 – 2006
- 26) ***Risk of adverse effects among elderly statin users***  
Principal Investigator: M. Tonelli  
Co-investigators: B. Manns, B. Hemmelgarn, P. Muntner  
Funding \$100,000  
Funding Source CIHR  
Years 2012-2015
- 27) ***Seeing the forests and the trees - Innovative approaches to exploring heterogeneity in systematic reviews of complex knowledge translation interventions to enhance policy decision making***  
Principal Investigator: J. Grimshaw  
Co-investigators: B. Manns, A. Edwards, N. Ivers, J. Lavis, D. Moher, A. Paprica, T. Ramsay, P. Sargious, K. Shojania, S. Straus, M Tonelli, A Tricco, C, Yu.  
Funding \$600,000  
Funding Source CIHR  
Years 2012-2015



- 28) *Implementation and evaluation of a clinical pathway for chronic kidney disease in primary care*  
Principal Investigator: B. Hemmelgarn  
Co-investigators: T. Braun, T. Noseworthy, B. Manns, M. Tonelli, K. Jindal, M. Jun, K. King-Shier, A. Levin, R. Lewanczuk, C. Naugler, P. Sargious, N. Scott-Douglas, S. Straus  
Funding: 674,412 total (3 years)  
Funding Source: CIHR  
Years: 2013 – 2016
- 29) *Epidemiology, costs and consequences of multimorbidity*  
Principal Investigator: M. Tonelli  
Co-investigators: B. Manns, T. Braun, M. Fortin, B. Hemmelgarn, M. James, S. Klarenbach, R. Lewanczuk, H. Quan, N Wiebe.  
Funding: 663,000 total (3 years)  
Funding Source: CIHR  
Years: 2014 – 2017

**IX. Invited Addresses:**

- June 2015 “An overview of Health Economics”  
Health Economics Course – Final Presentations and Overview to AHS  
Edmonton, AB
- June 2015 “An overview of activity based funding”  
Activity based funding workshop – Institute of Health Economics  
Edmonton, AB
- June 2015 “Listening, Learning and Leading: Canadians Seeking Solutions and Innovations  
to Overcome Chronic Kidney Disease (Can-SOLVE CKD)”  
National Kidney Foundation of Canada meeting  
Mont Tremblant, QC
- June 2015 “Using the knowledge to action cycle to improve timing of dialysis initiation”  
Ontario Renal Network Annual Conference  
Toronto, ON
- May 2015 “Health economics needs assessment, Alberta 2015” - Alberta Health  
Edmonton, Alberta
- May 2015 “Overcoming cost barriers: The ACCESS study”  
CIHR Institute of Nutrition, Metabolism and Diabetes Board meeting  
Calgary, Alberta
- April 2015 “An update on the Canadian Society of Nephrology: President’s Address”  
Canadian Society of Nephrology Annual General Meeting  
Montreal, QC
- April 2015 “Standardizing PD education”  
British Columbia Peritoneal Dialysis Days  
Vancouver, BC
- March 2015 “Timing of Dialysis Initiation”  
Alberta Nursing education day  
Calgary, AB
- Nov 2014 “The Canadian Society of Nephrology – an update on priorities”  
American Society of Nephrology Annual General Meeting  
Philadelphia, PA
- Nov 2014 “Comparing the health research priorities of researchers and patients”  
Canadian Health Funders Consortium Annual Meeting  
Ottawa, ON
- Oct 2014 “Increasing appropriate Timing of Dialysis Initiation”  
Lethbridge Nephrology group  
Lethbridge, AB

- Sept 2014 “Developing an evaluation strategy for Strategic Clinical Network Priorities”  
Alberta Health Services, Strategic Clinical Network Connects Conference  
Banff, AB
- Apr 2014 “From data to best practice: an overview of increasing the use of home dialysis  
therapies”  
Canadian Society of Nephrology Annual General Meeting  
Vancouver, BC
- Apr 2014 “Patient oriented research”  
Kidney Foundation of Canada Annual General Meeting  
Vancouver, BC
- Feb 2014 “Health Economics: An overview for clinicians”  
University of Calgary Master Clinician course  
Calgary, Alberta
- Dec 2013 “Patient engagement in setting research priorities”  
CIHR Institute of Nutrition, Metabolism and Diabetes conference  
Edmonton, AB
- Oct 2013 Using the knowledge to action cycle to improve management of patients with  
severe CKD nearly dialysis  
British Columbia Nephrology Days  
Vancouver, BC
- Oct 2013 “Copayment Elimination and Patient Education for the Prevention of Adverse  
Events in Chronic Disease StudY” (CoPAY), Alberta Health  
Calgary, AB
- June 2013 “Priority Setting Partnership for People with Kidney Failure on Dialysis”  
St Michael’s Hospital,  
Toronto, Ontario
- May 2013 “The impact of cost sharing for drugs on health outcomes and costs”  
Alberta Health  
Calgary, AB
- May 2013 “Timing of dialysis initiation”  
Presenter and organizer of symposium held at Annual CSN meeting,  
Montreal, Quebec
- March 2013 “Survey on the Barriers to Care for People with Chronic Health Conditions”  
Alberta Health Lunch and Learn  
Calgary, AB

- Feb 2013 “The role of mentoring in career progression”  
University of Calgary Internal Medicine Retreat Guest Speaker  
Calgary, AB
- Nov 2012 “Knowledge Translation in Nephrology”  
University of Calgary Citywide Nephrology Rounds  
Calgary, AB
- Nov 2012 “Knowledge Translation in Nephrology”  
University of Toronto Sunnybrook Hospital Nephrology Rounds  
Toronto, Ontario
- Nov 2012 “The impact of a management based eGFR report in CKD”  
Visiting Professor in the Division of Nephrology at the University of Toronto  
University of Toronto Grand Rounds  
Toronto, Ontario
- Oct 2012 “The impact of financial barriers on adherence to prescription drugs”  
Alberta Employers Committee on Health  
Edmonton, Alberta
- Oct 2012 “Peritoneal dialysis vs hemodialysis: A debate  
American Society of Nephrology  
San Diego, USA
- Sept 2012 “Using quality of life as a measure within studies to improve care in kidney  
failure” - Alberta EQ-5D workshop  
Canmore, Alberta
- April 2012 The Canadian Kidney Knowledge Translation and Generation Network  
Canadian Society of Nephrology Annual Meeting,  
St John’s, NFLD
- March 2012 “An overview of the Interdisciplinary Chronic Disease Collaboration”  
Alberta Health and Alberta Health Services  
Edmonton, AB
- Oct 2011 “Funding new pharmaceuticals: Seeking the right balance in publicly funded  
health care”  
Grand Medical rounds, Dalhousie University  
Halifax, NS
- Oct 2011 The impact of a management based eGFR report in CKD  
Nephrology rounds, Dalhousie University  
Halifax, NS
- June 2011 The impact of a management based eGFR report in CKD  
AKTN, University of Brisbane  
Queensland, Australia

- May 2011 The impact of a management based eGFR report in CKD  
Monash Medical Center, Monash University  
Victoria, Australia
- Mar 2011 Enzyme replacement therapy for Fabry's Disease: Does it matter?  
World Congress of Nephrology  
Vancouver, BC
- Mar 2011 The cost-effectiveness of statins in people at low cardiovascular risk  
Centre for Health Economics, Monash University  
Victoria, AustraliaAus
- Feb 2011 The impact of a management based eGFR report in CKD  
George Institute Camperdown, University of Sydney  
New South Wales, Australia
- Nov 2010 Improving Efficiency in Hospital Care  
Hospital Medicine Conference  
Calgary, Alberta
- Sept 2010 Recommendations for Commonly used Drugs in patients with Chronic Kidney  
Disease - Rural Continuing Medical Education  
Calgary, Alberta
- Sept 2010 Approaches to mitigating against methodologic bias in economic evaluations  
Invited presentation at *Methodology Forum: Prioritizing Methodological Research  
in Evaluation of Health Technologies* - Institute of Health Economics  
Edmonton, Alberta
- Mar 2010 Lunch and Learn – ICDC  
Alberta Health and Wellness  
Calgary, Alberta
- Oct 2009 “Will there be new cardiovascular therapies in the future: The perspective of the  
Common Drug Review”  
Invited presentation at the Annual Meeting of the Canadian Hypertension Society  
Edmonton, Alberta
- Oct 2009 “Evaluating the cost and cost-effectiveness of nocturnal hemodialysis”  
Invited podium presentation at the Amer. Society of Nephrology Annual meeting  
San Diego, California
- May 2008 “Funding new pharmaceuticals: Seeking the right balance in publicly funded  
health care”  
Keynote speaker, Resident Research Day  
Ottawa, ON

- Nov. 2008 “QALYs in Action: A Canadian Perspective” – Top of the Hill, Washington, DC
- Nov. 2008 “Randomized controlled Trials: Good as Gold” – Pre-course, American Society of Nephrology, Philadelphia, PA
- May 2008 “Therapeutics Debate”  
Chair of the “Therapeutics Debate” session  
Canadian Society of Nephrology Meeting  
London, ON
- May 2008 “Controversies in Mineral Metabolism”  
Visiting Speaker, Canadian Society of Nephrology Meeting  
London, ON
- May 2008 “The Canadian Common Drug Review: Past, present and future”  
ISPOR symposium (International Experiences of Centralized Reimbursement Reviews: Identifying Best Practices)  
Toronto, ON
- Mar 2008 “An update on anemia management in CKD”  
Visiting Speaker, Province-wide Nephrology Grand Rounds  
Saskatoon, SK
- Mar 2008 “CEDAC: Progress and Challenges”  
Pharmaceutical Directors Forum  
Ottawa, ON
- Oct. 2007 “Cost effectiveness of ESAs in CKD”  
Visiting Speaker, Nephrology Grand Rounds  
London, ON
- Oct. 2007 “Effect of Frequent NHD on LVH and Quality of Life”  
Annual PreASN Visiting Speaker  
London, ON
- Oct. 2007 “Economic Evaluation: The nuts and bolts of “Why and how?””  
Visiting Speaker, Department of Clinical Epidemiology  
St John, NFLD
- Oct. 2007 “CEDAC: Annual Update”  
CADTH Board of Directors Meeting  
Whitehorse, YK
- May 2007 “Updated CSN Anemia Clinical Practice Guidelines”  
Canadian Society of Nephrology Annual Meeting  
Halifax, Nova Scotia

- May 2007 “Surrogates Endpoints: Challenges Created for Post-Licensing Advisory Bodies”  
CADTH Annual Symposium Precourse  
Ottawa, Ontario
- May 2007 “Expensive Drugs for Rare Diseases: Perspectives from CEDAC”  
Invited podium presentation at CADTH Annual Symposium  
Ottawa, Ontario
- Nov. 2006 “The impact of education on the use of self care dialysis”  
Invited podium presentation at the Amer. Society of Nephrology Annual meeting  
San Francisco, California
- Nov. 2006 “The cost effectiveness of nocturnal hemodialysis”  
Invited podium presentation at the Amer. Society of Nephrology Annual meeting  
San Francisco, California
- Nov. 2005 “Enzyme Replacement Therapy for Fabry's Disease should be Publicly Funded:  
Yes or No”  
Presentation as a debater at the 2005 "CSN in America" event  
American Society of Nephrology Annual Meeting, Philadelphia, PA
- Sept. 2005 Health Economics for Clinicians: 2 day course  
Two-hour lecture on “Using Decision Analysis in Economic Evaluation”  
NewCastle, UK
- May 2005 The cost of maintaining vascular access in hemodialysis patients  
Presentation at a symposium at the Can. Society of Nephrology Annual Meeting  
Calgary, AB
- May 2005 Chair of a symposium at the Canadian Society of Nephrology Annual Meeting  
Symposium on Clinical Research in Kidney Diseases  
Calgary, AB
- April 2005 Balancing Economics, Science and Ethics: Considerations for the Approval of  
Novel Therapies in CKD  
Presentation at Alberta Nephrology Days  
Banff, AB
- Mar 2005 Surrogate markers and their implications for funding new pharmaceuticals  
Presentation to CEDAC at annual retreat  
Victoria, BC
- Jan 2004 Activated Protein C in Severe Sepsis: A policy perspective  
Presentation to the Calgary Caucus of the Alberta Government (including Ralph  
Klein, Premier and Gary Mar, Health Minister)  
Calgary, Alberta

- Sept. 2003 Economic implications of population-based chronic kidney disease intervention  
Prevention in Renal Disease Annual Conference  
Toronto, Ontario
- Sept. 2003 Cost-effectiveness of Activated Protein C  
Plenary session at International Congress meeting of the German Sepsis Society  
Weimar, Germany
- May 2003 Costs: Normalization of Hemoglobin with Erythropoietin.  
Presented at the Canadian Society of Nephrology Annual meeting  
St. John's, Newfoundland
- May 2003 Economic considerations in Choices of End Stage Renal Disease Therapeutic  
Modality  
Presented at Alberta Nephrology Days  
Kananaskis, Alberta
- April 2003 Economic evaluation in health care: An introduction and application to patients  
with liver and gastrointestinal disease. Alberta GI retreat  
Banff, Alberta
- Mar. 2003 Interpretation and Health Policy Implications of Cost Effectiveness Analysis: A  
case study of Activated Protein C for severe sepsis  
Pre-conference workshop at Canadian Association for Population Therapeutics  
Annual Conference  
Quebec City, Quebec
- Sept. 2002 The cost of acute renal failure requiring dialysis in the intensive care unit: The  
clinical and resource implications of renal recovery.  
Presented at Alberta Nephrology Days  
Calgary, Alberta
- Feb. 2002 An Education Program for Clinicians in the Evaluation of Economic and  
Humanistic Outcomes of Health Care Interventions  
Presented two lectures on decision analysis within economic evaluation at a six  
day course attended by physicians with an interest in health economics  
Edmonton, Alberta
- July 2001 Methodological issues in the economic evaluation of end-stage renal disease  
Presented at the International Health Economics Association meeting  
York, United Kingdom
- Mar 2001 To reuse or not to reuse? An economic evaluation of hemodialyser reuse vs  
conventional single use hemodialysis  
Presented at the Canadian Society of Nephrology annual meeting  
Vancouver, Canada



- Nov. 2000    Economic Evaluation of Xenotransplantation  
Presented at a conference entitled “The Perils and Promise of  
Xenotransplantation”, a citizen’s jury commissioned by Health Canada  
Calgary, Alberta
- Sept. 1998    Hyperhomocysteinemia and the Risk for Atherosclerotic Vascular Disease in  
Patients with End-Stage Renal Disease  
Presented at the annual meeting of the Royal College of Physicians and Surgeons  
Toronto, Ontario
- May 1998    Hyperhomocysteinemia and the Risk for Atherosclerotic Vascular Disease in  
Patients with End-Stage Renal Disease  
Resident Research Day  
Dept of Internal Medicine, Univ. of Calgary
- April 1996:    Antituberculous drug resistance in immigrants  
Resident Research Day  
Dept of Internal Medicine, Univ. of Calgary
- Sept. 1995    Resistance to antituberculous medications in immigrants to Alberta with  
tuberculosis  
Canadian Resident-Fellow Competition in Respiratory Research  
St. Sauveur, Quebec

## X. Publications (peer reviewed, in press) (trainees underlined)

01. Liang X, Tang M, **Manns B**, Babiuk LA, Zamb TJ. Identification and Deletion Mutagenesis of the Bovine Herpesvirus 1dUTPase Gene and a Gene Homologous to Herpes Simplex Virus UL49.5. *Virology* 1993; 195: 42-50.
02. **Manns BJ**, Baylis BW, Urbanski SJ, Gibb AP, Rabin HR. Paracoccidioidomycosis: Case report and review of the literature. *Clinical Infectious Diseases* 1996; 23: 1026-32.
03. **Manns BJ**, Fanning EA, Cowie RL. Antituberculous drug resistance in immigrants to Alberta, Canada with tuberculosis, 1982 - 1994. *International Journal of Tuberculosis and Lung Disease* 1997; 1: 225-230.
04. **Manns BJ**, Burgess ED, Parsons HG, Schaefer JP, Hyndman ME, Scott-Douglas, NW. Hyperhomocysteinemia, Anticardiolipin Antibody Status and the Risk for Vascular Access Thrombosis in Patients with End-Stage Renal Disease on Hemodialysis. *Kidney International* 1999; 55: 315-320.
05. **Manns BJ**, Burgess ED, Parsons HG, Schaefer JP, Hyndman ME, Scott-Douglas, NW. Hyperhomocysteinemia and the Risk for Atherosclerotic Vascular Disease in Patients with End-Stage Renal Disease. *American Journal of Kidney Diseases*, 1999; 34: 669-677
06. **Manns BJ**, Taub K, Donaldson C. Economic evaluation and end-stage renal disease: From basics to bedside. *American Journal of Kidney Diseases* 2000; 36: 12-28. (**In-Depth Review**)
07. **Manns BJ**, Mortis GP, Taub KJ, McLaughlin K, Donaldson C, Ghali WA. Overview of the Southern Alberta Renal Program Database: A prototype for patient management and research initiatives. *Clin Invest Med* 2001; 24(4): 164-170.
08. **Manns BJ**, Taub K, Donaldson C. Economic evaluation and the treatment of end-stage renal disease. *Current Opinion in Nephrology and Hypertension*. 2001; 10: 295-299. (**Special Article**)
09. **Manns BJ**, Hyndman ME, Burgess ED, Parsons HG, Schaefer JP, Snyder F, Scott-Douglas NW. Oral vitamin B12 and high-dose folic acid in hemodialysis patients with hyperhomocyst(e)inemia: A randomized clinical trial. *Kidney International*. 2001; 59: 1103-09.
10. Devereaux PJ, **Manns BJ**, Ghali WA, Quan H, Guyatt GH. Reviewing the reviewers: the quality of reporting in three review journals. *Canadian Medical Association Journal* 2001; 11: 1573-1576.
11. Devereaux PJ, **Manns BJ**, Ghali WA, Quan H, Lacchetti C, Montori VM, Bhandari M, Guyatt GH. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. *JAMA*. 2001; 285: 2000-2003.
12. McLaughlin K, **Manns BJ**, Culleton B, Donaldson C, Taub K. Early referral of patients with progressive renal insufficiency is cost-effective. *Am J Kidney Dis* 2001; 38: 1122-1128. (**Fast-tracked**)

13. **Manns BJ**, Taub K, Richardson, R, Donaldson C. To reuse or not to reuse? An economic evaluation of hemodialyser reuse vs conventional single use hemodialysis for chronic hemodialysis patients. *Intl. J. Tech Ass Health Care* 2002; 18: 81-94.
14. Devereaux PJ, Bhandari M, Montori VM, **Manns BJ**, Ghali WA, Guyatt GH. Double blind, you are the weakest link -- good-bye! [Editorial]. *ACP J CLUB*. 2002. Jan-Feb; A11-12
15. Helen Lee, **Braden J. Manns**, Ken Taub, William A. Ghali, Stafford Dean, David Johnson, Cam Donaldson. Cost analysis of ongoing care of patients with end-stage renal disease: The impact of dialysis modality and dialysis access. *Am J Kidney Diseases* 2002; 40: 611-622.
16. Montori VM, Bhandari M, Devereaux PJ, **Manns BJ**, Ghali WA, Guyatt GH. In the dark: the reporting of blinding status in randomized controlled trials. *J Clin Epidemiol* 2002; 55:42-45.
17. Devereaux PJ, **Manns BJ**, Ghali WA, Quan H, Guyatt GH. The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to the consolidated standards of reporting trials (CONSORT) checklist. *Controlled Clinical Trials*. 2002; 23: 380-388
18. **Manns BJ**, Johnson JA, Taub K, Mortis G, Ghali WA, Donaldson C. Dialysis adequacy and health-related quality of life in patients on hemodialysis. *ASAIO* 2002; 48: 565-9.
19. Marcello Tonelli, **Braden J. Manns**, David Feller-Kopman. Acute Renal Failure in the Intensive Care Unit: A Meta-Analysis of the Impact of Dialytic Modality on Mortality and Renal Recovery. *Am J Kidney Dis* 2002; 40: 875-885.
20. **Braden J. Manns**, Helen Lee, Christopher James Doig, David Johnson, Cam Donaldson. An Economic Evaluation of Activated Protein C Treatment in Severe Sepsis. *New England Journal of Medicine*, 2002; 347: 993-1000 (**Special Article**).
21. Matthew Eric Hyndman, **Braden J. Manns**, Floyd F.Snyder, Peter J. Bridge, Nairne W. Scott-Douglas, Ernest Fung, Howard G. Parsons. Vitamin B<sub>12</sub> decreases but does not normalize Homocysteine and Methylmalonic Acid in End-Stage Renal Disease (ESRD): A Link with Glycine Metabolism and possible explanation of hyperhomocysteinemia in ESRD. *Metabolism* 2003; 52(2):168-72.
22. **Braden J. Manns**, Christopher James Doig, Helen Lee, Stafford Dean, Marcello Tonelli, David Johnson, Cam Donaldson. The cost of acute renal failure requiring dialysis in the intensive care unit: The clinical and resource implications of renal recovery. *Critical Care Medicine* 2003; 31(2):449-55.
23. Kevin McLaughlin, **Braden Manns**, Garth Mortis, Ronald Hons, Ken Taub. Why Patients With End-Stage Renal Disease Do Not Select Self-Care Dialysis As A Treatment Option. *Am J Kidney Dis* 2003 41(2):380-5.

24. **Manns BJ**, Meltzer D, Taub K, Donaldson C. Illustrating the impact of including future costs in economic evaluations: An application to end-stage renal disease care. *Health Economics* 2003; 12(11), 949-958.
25. Marcello Tonelli, Wolfgang Winkelmayr, Kailash K. Jindal, William F. Owen, Jr., **BJ Manns**. The Cost Effectiveness of Different Hemoglobin Targets in Hemodialysis Patients Treated with Erythropoietin. *Kidney Int*, 2003; 64: 295-304.
26. Kaplan G, **Manns B**. Renal regulation. The keys to preventing chronic renal failure. *The Canadian Journal of CME* 2003; 15(2): 55-64.
27. **Manns BJ**, Johnson JA, Taub K, Mortis G, Ghali WA, Donaldson C. Quality of life in patients treated with hemodialysis or peritoneal dialysis: What are the important determinants? *Clinical Nephrology* 2003; 60: 341-51.
28. Hemmelgarn B, **Manns B**, Ghali WA. Adapting the Charlson Comorbidity Index for use in patients with ESRD. *Am J Kidney Dis*, 2003; 42:125-132.
29. Pannu N, **Manns B**, Lee H, Tonelli M. Systematic Review of the Impact of N-Acetylcysteine on Contrast Nephropathy. *Kidney Int*, 2004; 65:1366-74.
30. Doig CJ, Laupland KB, Zygun DA, **Manns BJ**. The epidemiology of severe sepsis syndrome and its treatment with recombinant human activated protein C. *Expert Opinion in Pharmacotherapy*, 2003; 4:1789-99.
31. Doig CJ, Zygun DA, Delaney A, **Manns BJ**. Drotrecogin alfa (activated): an effective and cost efficient treatment for severe sepsis. *Expert Review of Pharmacoeconomics & Outcomes Research*, 2004; 4: 15–26.
32. Lee H, Donaldson C, Doig C, Ghali WA, Johnson D, **Manns B**. A detailed cost analysis of the care for survivors of severe sepsis: An opportunity to improve efficiency? *Crit Care Med* 2004; 32: 981-5.
33. Devereaux PJ, Choi PTL, El-Dika S, Bhandari M, Montori VM, Schünemann HJ, Garg AX, Busse JW, Heels-Ansdell D, Ghali WA, **Manns BJ**, Guyatt GH. An observational study found that authors of randomized controlled trials frequently used concealment of randomization and blinding, despite the failure to report these methods. *J Clin Epidemiol*. 2004; 57: 1232-1236
34. Marcello Tonelli, Brenda Hemmelgarn, **Braden Manns**, George Pylypchuk, Clara Bohm, Karen Yeates, Sita Gourishankar, John S. Gill. Death and Renal Transplantation Rates in Aboriginal Canadians Receiving Dialysis Treatment. *CMAJ*; 2004; 171: 577-82.
35. **Manns BJ**, Stevens, L, Miskulin D, Owen WF, Winkelmayr WW, Tonelli M. A critical appraisal of sevelamer in ESRD and its potential economic impact in Canada and the United States. *Kidney Int*, 2004; 66(3):1239-47
36. Fiona M Shrive, **Braden J Manns**, P. Diane Galbraith, Merrill L Knudtson, William A Ghali. An Economic Evaluation of Sirolimus-Eluting Stents. *CMAJ*, 2005;172(3):345-51.

37. **Braden Manns**, Marcello Tonelli, Serdar Yilmaz, Helen Lee, Kevin Laupland, Scott Klarenbach, Val Radkevich, Brendan Murphy. Establishment and maintenance of vascular access in incident hemodialysis patients: A prospective cost analysis. *JASN*; 2005; 16: 201-9.
38. Walsh M, Culleton BA, Tonelli M, **Manns BJ**. A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism and health-related quality of life. *Kidney Int*, 2005; 67: 1500-1508.
39. Tonelli M, Hemmelgarn B, **Manns BJ**, Pylypchuk G, Bohm C, Yeates K, Gourishankar S, Gill J for the Canadian Nephrology Young Investigators Group. Technique Failure and Mortality in Aboriginal Canadians on Peritoneal Dialysis. *JASN* 2005; 16: 484-8.
40. **Manns BJ**, Taub K, VanderStraeten C, Jones H, Mills C, Visser M. A patient-centered educational intervention to improve the utilization of “self-care dialysis” among predialysis patients: A randomized controlled trial. *Kidney Int* 2005 68:1777-83
41. Fiona M Shrive, William A Ghali , Steven Lewis, Cam Donaldson, Merrill L Knudtson, **Braden J Manns**. Sirolimus-eluting Stents at 58 K per QALY: Now What? *Can J Card* 2005; 21: 783-788.
42. Brauer C, **Manns BJ**, Donaldson C, Buckley R. An economic evaluation of operative versus non-operative management of displaced intra-articular calcaneal fractures. *Journal of Bone and Joint Surgery*, 2005; 87: 2741-9.
43. Kaplan GG, **Manns BJ**, McLaughlin K. Heparin Induced Thrombocytopenia Secondary to Intraperitoneal Heparin Exposure. *Nephrol Dial Transplant*, 2005; 20: 2561-2.
44. Heitman S, **Manns BJ**, Hilsden R, Fong A, Dean S, Romagnuolo J. Cost-Effectiveness of CT Colonography vs Colonoscopy for Colorectal Cancer Screening. *CMAJ* 2005; 173:877-81.
45. Delaney A, Bagshaw S, Ferland A, **Manns BJ**, Laupland K, Doig CJ. A Systematic Evaluation of the Quality of Meta-analyses in the Critical Care Literature. *Crit Care Med* 2005; 9: R575-82.
46. Bagshaw SM, McAlister FA, **Manns BJ**, Ghali WA. Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. *Arch Intern Med*. 2006; 166:161-6.
47. Tonelli M, Klarenbach S, Jindal K, **Manns BJ**. Economic implications of screening strategies in arteriovenous fistulae. *Kidney Int*, 2006 Jun;69(12):2219-26.
48. Klarenbach SW, Pannu N, Tonelli MA, **Manns BJ**. Cost-effectiveness of hemofiltration to prevent contrast nephropathy in patients with chronic kidney disease. *Crit Care Med*. 2006; 34: 1044-51.

49. Walsh M, **Manns BJ**, Klarenbach S, Quinn R, Tonelli M, Culleton BF. The effects of nocturnal hemodialysis compared to conventional hemodialysis on change in left ventricular mass: Rationale and study design of a randomized controlled pilot study. *BMC Nephrol*. 2006; 7: 2.
50. Cox H, Laupland K, **Manns BJ**. Economic Evaluation in Critical Care Medicine. *Journal of Critical Care*, 2006 Jun;21(2):117-24.
51. Culleton BF, **Manns BJ**, Zhang J, Tonelli M, Klarenbach S, Hemmelgarn BR. Impact of anemia on hospitalization and mortality in older adults. *Blood*. 2006;107:3841-6.
52. Devereaux PJ, Bhandari M, Montori VM, **Manns BJ**, Ghali WA, Guyatt GH. Double blind, you are the weakest link--goodbye! *Equine Vet J*. 2005; 37: 557-8.
53. Hemmelgarn BR, Moist L, Pilkey RM, Lok C, Dorval M, Tam PY, Berall MJ, Leblanc M, Toffelmire EB, **Manns BJ**, Scott-Douglas N. Prevention of catheter lumen occlusion with rT-PA versus heparin (Pre-CLOT): Study protocol of a randomized trial. *BMC Nephrol*. 2006; 11;7:8.
54. Walsh M, **Manns BJ**. Oral mycophenolate led to more complete remissions than intravenous cyclophosphamide for active lupus nephritis. *ACP J Club*. 2006; 144(3):74.
55. Laupland KB, Lee H, Gregson DB, **Manns BJ**. Cost of intensive care unit-acquired bloodstream infections. *J Hosp Infect*. 2006; 1June;63(2):124-32.
56. Hemmelgarn BR, Zhang J, **Manns BJ**, Tonelli M, Larsen E, Ghali WA, Southern DA, McLaughlin K, Mortis G, Culleton BF. Progression of kidney dysfunction in the community-dwelling elderly. *Kidney Int*. 2006 une;69(12):2155-61.
57. **Manns BJ**, Owen WF, Winkelmayr W, Devereaux PJ, Tonelli, M. Surrogate Markers in Clinical Studies. Problems Solved or Created? *Am J Kidney Dis* 2006 Jul 48(1):159-66.
58. McLaughlin K, **Manns BJ**, Nickerson P. The routine use of high-resolution immunological screening of recipients of primary deceased donor kidney allografts is cost-effective. *Transplantation*. 2006; 81:1278-84.
59. James M, **Manns BJ**. N-acetylcysteine prevented contrast-medium-induced nephropathy in primary angioplasty. *ACP J Club*. 2006 Nov-Dec;145(3):63.
60. Tonelli M, Klarenbach S, **Manns BJ**, Culleton B, Hemmelgarn B, Bertazzon S, Wiebe N, Gill JS; Alberta Kidney Disease Network. Residence location and likelihood of kidney transplantation. *CMAJ*. 2006 Aug 29;175(5):478-82.
61. Barnieh L, Baxter D, Boiteau P, **Manns BJ**, Doig C. Benchmarking performance in organ donation programs: dependence on demographics and mortality rates. *Can J Anaesth*, 2006 July;53(7):727-31.

62. Tonelli M, Hemmelgarn B, Kim AK, Bertazzon S, Klarenbach S, **Manns BJ**, Wiebe N, Culleton B, Gill JS; Alberta Kidney Disease Network. Association between residence location and likelihood of kidney transplantation in Aboriginal patients treated with dialysis in Canada. *Kidney Int.* 2006 Sep;70(5):924-30.
63. Hemmelgarn BR, Chu S, Wiebe N, Culleton BF, **Manns BJ**, Klarenbach S, Khan NA, Gourishankar S, Yeates KE, Gill JS, Tonelli M. Differences in use of peritoneal dialysis and survival among East Asian, Indo Asian, and white ESRD patients in Canada. *Am J Kidney Dis.* 2006 Dec;48(6):964-71.
64. Delaney A, Bagshaw SM, Ferland A, Laupland K, **Manns BJ**, Doig C. The quality of reports of critical care meta-analyses in the Cochrane Database of Systemic Reviews: an independent appraisal. *Crit Care Med.* 2007 Feb;35(2):589-94.
65. Oliver M, Quinn R, Richardson E, Kiss A, Lamping D, **Manns BJ**. Home care assistance and the utilization of peritoneal dialysis. *Kidney Int.* 2007; 71: 673-8.
66. Shrive F, Ghali W, Johnson J, Donaldson C, **Manns BJ**. Use of the U.S. and U.K. scoring algorithm for the EuroQol-5D in an economic evaluation of cardiac care. *Med Care.* 2007 Mar;45(3):269-73
67. Gooch K, Culleton B, **Manns BJ**, Zhang J, Alfonso H, Tonelli M, Frank C, Klarenbach S, Hemmelgarn B. NSAID use and progression of chronic kidney disease. *Am J Med.* 2007 Mar;120(3):280.e1-7.
68. Hemmelgarn BR, **Manns BJ**, Zhang J, Tonelli M, Klarenbach S, Walsh M, Culleton BF. Association between Multidisciplinary care and survival for elderly patients with chronic kidney disease. *J Am Soc Nephrol*, 2007 Mar;18(3):993-9.
69. Walsh M, Tonelli M, Jayne D, **Manns BJ**. Surrogate end points in clinical trials: the case of anti-neutrophil cytoplasm antibody-associated vasculitis. *J Nephrol* 2007 Mar-Apr;20(2):119-29.
70. Graham A, Shrive F, Ghali W, **Manns BJ**, Grondin S, Finley R, Clifton J. Defining the optimal treatment of locally advanced esophageal cancer: a systematic review and decision analysis. *Ann Thorac Surg.* 2007 Apr;83(4):1257-64.
71. Joffres M, Campbell N, **Manns BJ**, Tu K. Estimate of the benefits of a population-based reduction in dietary sodium additives on hypertension and its related health care costs in Canada. *Can J Cardiol.* 2007 May 1;23(6):437-43.
72. Tonelli M, Hemmelgarn B, Gill JS, Chou S, Culleton B, Klarenbach S, **Manns BJ**, Wiebe N, Gorishankar S. Patient and allograft survival of Indo Asian and East Asian dialysis patients treated in Canada. *Kidney Int* 2007 Jun 6.
73. Quinn RR, **Manns BJ**, McLaughlin KM. Restricting cadaveric kidney transplantation based on age: the impact on efficiency and equity. *Transplant Proc.* 2007 Jun;39(5):1362-7.

74. **Manns BJ**, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M. Economic evaluation of sevelamer in patients with end-stage renal disease. *Nephrol Dial Transplant* 2007 June; 22(10):2867-78.
75. Mendelssohn DC, Muirhead N, **Manns BJ**. Managing anemia. What do we do now? Views from Canada. *Nephrol News Issues*. 2007 June;21(7):55-7.
76. Tonelli M, Hemmelgarn B, Culleton B, Klarenbach S, Gill JS, Wiebe N, **Manns BJ**. Mortality of Canadians treated by peritoneal dialysis in remote locations. *Kidney Int* 2007 Jul 18.
77. **Manns BJ**, Mendelssohn DC, Taub KJ. The economics of end-stage renal disease care in Canada: incentives and impact on delivery of care. *Int J Health Care Finance Econ*. 2007 July 20.
78. Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas, N, Quinn R, Tonelli M, Donnelly S, Friedrich MG, Kumar A, Mahallati H, Hemmelgarn BR, and **Manns BJ**. The Impact of Frequent Nocturnal Hemodialysis and Conventional Hemodialysis on Left Ventricular Mass and Quality of Life. *JAMA*, 2007; 298(11): 1291-99
79. Komenda P, Levin A, **Manns B**. The economics of home nocturnal hemodialysis: how should we cost the benefits? *Clin Nephrol* 2007; 68(3):151-8.
80. Walsh M, James M, Jayne D, Tonelli M, **Manns B**, Hemmelgarn B. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. *Clin J Am Soc Nephrol* 2007;2(5):968-75.
81. Brar SS, **Manns BJ**. Activated protein C: cost-effective or costly? *Crit Care* 2007; 11(5):164.
82. Tonelli M, Wiebe N, Culleton B, Lee H, Klarenbach S, Shrive F, **Manns B**; AKDN. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. *Nephrol Dial Transplant* 2007; 22(10): 2856-66.
83. Gao S, **Manns BJ**, Culleton BF, Tonelli M, Quan H, Crowshoe L, Ghali WA, Svenson LW, Hemmelgarn BR; Alberta Kidney Disease Network. Prevalence of chronic kidney disease and survival among aboriginal people. *J Am Soc Nephrol* 2007; 18(11): 2953-9.
84. Tonelli M, **Manns B**, Culleton B, Klarenbach S, Hemmelgarn B, Wiebe N, Gill JS; AKDN. Association between proximity to the attending nephrologist and mortality among patients receiving hemodialysis. *CMAJ* 2007; 177(9):1039-44.
85. Wang W, Murphy B, Yilmaz S, Tonelli M, Macrae J, **Manns BJ**. Comorbidities do not influence primary fistula success in incident hemodialysis patients: a prospective study. *Clin J Am Soc Nephrol* 2008; 3(1): 78-84.
86. Wu CM, McLaughlin K, Lorenzetti DL, Hill MD, **Manns BJ**, Ghali WA. Early risk of stroke after transient ischemic attack: a systematic review and meta-analysis. *Arch Intern Med* 2007; 167(22):2417-22.



87. Wang W, Tonelli M, Hemmelgarn B, Gao S, Johnson JA, Taub K, **Manns B**. The effect of increasing dialysis dose in overweight hemodialysis patients on quality of life: a 6-week randomized cross over trial. *Amer J Kidney Dis* 2008 51(5):796-803.
88. Pannu N, Klarenbach S, Wiebe N, **Manns B**, Tonelli M. Renal replacement in patients with acute renal failure: A systematic review. *JAMA* 2008; 299(7):793-805
89. Shane Sinclair, Neil A. Hagen, Carole Chambers, **Braden Manns**, Anita Simone, George P. Browman. Accounting for reasonableness: Exploring the personal internal framework affecting decisions about cancer drug funding. *Health Policy* 2008; 86: 381–390.
90. Tierney M, **Manns B**, Members of the Canadian Expert Drug Advisory Committee. Optimizing the use of prescription drugs in Canada through the Common Drug Review. *CMAJ* 2008, 178(4):432-5.
91. Al-Ghonaim M, **Manns BJ**, Hirsch DJ, Gao Z, Tonelli M; Alberta Kidney Disease Network. Relation between access blood flow and mortality in chronic hemodialysis patients. *Clin J Am Soc Nephrol*, 2008, 3(2):387-91.
92. James MT, Conley J, Tonelli M, **Manns BJ**, MacRae J, Hemmelgarn BR; Alberta Kidney Disease Network. Meta – analysis: antibiotics for prophylaxis against hemodialysis catheter-related infections. *Ann Intern Med*, 2008, April;148(8):596-605.
93. McLaughlin K, Jones H, Vanderstraeten C, Mills C, Visser M, Taub K, **Manns BJ**. Why do patients choose self-care dialysis? *Nephrol Dial Transplant*, 2008 June.
94. Clement ‘nee Shrive’ FM, Ghali WA, Donaldson C, **Manns BJ**. The impact of using different costing methods on the results of an economic evaluation of cardiac care: microcosting vs gross-costing approaches. *Health econ.* 2008 July 10.
95. Heitman SJ, Au F, **Manns BJ**, McGregor SE, Hilsden RJ. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy. *Clin Gastroenterol Hepatol* 2008 August;6(8):912-917.
96. **BJ Manns**, CT White, F Madore, LM Moist, SW Klarenbach, BJ Barrett, RN Foley, BF Culleton, M Tonelli. Introduction to the Canadian Society of Nephrology Clinical Practice Guidelines for the management of anemia associated with chronic kidney disease. *Kidney Int* August 2008;74(110):S1-S3.
97. CT White, **BJ Manns**, F Madore, LM Moist, SW Klarenbach, BJ Barrett, RN Foley, BF Culleton, M Tonelli. Clinical Practice Guidelines for evaluation of anemia. *Kidney Int* August 2008;74(110):S4-S6.
98. F Madore, CT White, **BJ Manns**, LM Moist, SW Klarenbach, BJ Barrett, RN Foley, BF Culleton, M Tonelli. Clinical Practice Guidelines for assessment and management of iron deficiency. *Kidney Int* August 2008;74(110):S7-S11.

99. LM Moist, F Madore, CT White, **BJ Manns**, SW Klarenbach, BJ Barrett, RN Foley, BF Culleton, M Tonelli. Clinical Practice Guidelines for evidence-based use of erythropoietic-stimulating agents. *Kidney Int* August 2008;74(110):S12-S18.
100. SW Klarenbach, LM Moist, F Madore, CT White, **BJ Manns**, BJ Barrett, RN Foley, BF Culleton, M Tonelli. Clinical Practice Guidelines for supplemental therapies and issues. *Kidney Int* August 2008;74(110):S19-S24.
101. Heitman SJ, Au F, **Manns BJ**, McGregor SE, Hilsden RJ. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy. *Clin Gastroenterol Hepatol*. 2008 August;6(8):912-917.
102. James MT, Laupland KB, Tonelli M, **Manns BJ**, Culleton BF, Hemmelgarn BR; Alberta Kidney Disease Network. Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis. *Arch Intern Med*. 2008 Nov. 24;168(21):2333-9.
103. Levin A, Hemmelgarn B, Culleton B, Tobe S, McFarlane P, Ruzicka M, Burns K, **Manns B**, White C, Madore F, Moist L, Klarenbach S, Barrett B, Foley R, Jindal K, Senior P, Pannu N, Shurraw S, Akbari A, Cohn A, Reslerova M, Deved V, Mendelssohn D, Nesrallah G, Kappel J, Tonelli M; Canadian Society of Nephrology. Guidelines for the management of chronic kidney disease. *CMAJ*. 2008 Nov 18;179(11):1154-62.
104. Gao S, **Manns BJ**, Culleton BF, Tonelli M, Quan H, Crowshoe L, Ghali WA, Svenson LW, Ahmed S, Hemmelgarn BR; Alberta Kidney Disease Network. Access to health care among status Aboriginal people with chronic kidney disease. *CMAJ*. 2008 Nov 4;179(10):1007-12.
105. **Manns BJ**. Brand-name drugs are not more effective than generic versions for treating cardiovascular disease. *Ann Intern Med*. 2009 150(8):JC4-6.
106. Tonelli M, Hemmelgarn B, Reiman T, **Manns B**, Reaume MN, Lloyd A, Wiebe N, Klarenbach S. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. *CMAJ*. 2009 May 26;180(11):E62-71
107. James MT, Quan H, Tonelli M, **Manns BJ**, Faris P, Laupland KB, Hemmelgarn BR; Alberta Kidney Disease Network. CKD and risk of hospitalization and death with pneumonia. *Am J Kidney Dis*. 2009 Jul;54(1):24-32
108. Tonelli M, Wiebe N, Hemmelgarn B, Klarenbach S, Field C, **Manns B**, Thadhani R, Gill J; Alberta Kidney Disease Network. Trace elements in hemodialysis patients: a systematic review and meta-analysis. *BMC Med*. 2009 May 19;7:25
109. Heitman SJ, Ronksley PE, Hilsden RJ, **Manns BJ**, Rostom A, Hemmelgarn BR. Prevalence of adenomas and colorectal cancer in average risk individuals: A systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2009 Jun 9. [Epub ahead of print]

110. Clement FM, Klarenbach S, Tonelli M, Johnson JA, **Manns BJ**. The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis. *Arch Intern Med*. 2009 Jun 22;169(12):1104-12.
111. Chiasson TC, **Manns BJ**, Stelfox HT. An economic evaluation of venous thromboembolism prophylaxis strategies in critically ill trauma patients at risk of bleeding. *PLoS Med*. 2009 Jun 23;6(6):e1000098. Epub 2009 Jun 23
112. **Manns BJ**, Walsh M, Culleton B, Hemmelgarn B, Tonelli M, Schorr M, Klarenbach S; Alberta Kidney Disease Network. Nocturnal hemodialysis does not improve overall measures of quality of life compared to conventional hemodialysis. *Kidney Int* 2009;75: 542–549.
113. Muntner P, Mann D, Razzouk L, Klarenbach S, **Manns B**, Tonelli M, Farkouh ME. Is measuring C-reactive protein useful for guiding treatment in women  $\geq 60$  years and men  $\geq 50$  years of age? *Am J Cardiol* 2009; 104: 354-8.
114. Wu CM, **Manns BJ**, Hill MD, GHali WA, Donaldson C, Buchan AM. Rapid evaluation after high risk TIA is associated with lower stroke risk. *Can J Neurol Sci* 2009 July; 36: 450-5.
115. Tonelli M, Wang W, Hemmelgarn B, Lloyd A, **Manns B**; Alberta Kidney Disease Network. Phosphate removal with several thrice weekly dialysis methods in overweight hemodialysis patients. *Am J Kidney Dis*. 2009 Dec;54(6):1108-15.
116. Klarenbach S, **Manns B**, Pannu N, Clement FM, Wiebe N, Tonelli M; Alberta Kidney Disease Network. Economic evaluation of continuous renal replacement therapy in acute renal failure. *Int J Technol Assess Health Care*. 2009; 25: 331-8.
117. Clement FM, Harris A, Li JJ, Yong K, Lee KM, **Manns BJ**. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. *JAMA*. 2009 Oct 7;302(13):1437-43.
118. Hemmelgarn BR, Clement F, **Manns BJ**, Klarenbach S, James MT, Ravani P, Pannu N, Ahmed SB, MacRae J, Scott-Douglas N, Jindal K, Quinn R, Culleton BF, Wiebe N, Krause R, Thorlacius L, Tonelli M. Overview of the Alberta Kidney Disease Network. *BMC Nephrol*. 2009 Oct 19;10:30.
119. Deved V, Poyah P, James MT, Tonelli M, **Manns BJ**, Walsh M, Hemmelgarn BR; Alberta Kidney Disease Network. Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis. *Am J Kidney Dis*. 2009 Dec;54(6):1089-97.
120. Klarenbach S, **Manns B**. Economic evaluation of dialysis therapies. *Semin Nephrol*. 2009 Sep;29(5):524-32.
121. James MT, **Manns BJ**, Hemmelgarn BR, Ravani P; Alberta Kidney Disease Network. What's next after fistula first: is an arteriovenous graft or central venous catheter preferable when an arteriovenous fistula is not possible? *Semin Dial*. 2009 Sep-Oct;22(5):539-44.

122. Walsh M, **Manns BJ**, Klarenbach S, Tonelli M, Hemmelgarn B, Culleton B. The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trial. *Hemodial Int.* 2009; epub
123. Barnieh L, McLaughlin K, **Manns B**, Klarenbach S, Yilmaz S, Hemmelgarn B; Alberta Kidney Disease Network. Development of a survey to identify barriers to living donation in kidney transplant candidates. *Prog Transplant.* 2009; 19: 304-311.
124. Hemmelgarn B, Manns B, Lloyd A, James MT, Klarenbach S, Quinn R, et al. Relation Between Kidney Function, Proteinuria, and Adverse Outcomes. *JAMA.* 2010;303:423-29.
125. Al-Ghamdi G, Hemmelgarn B, Klarenbach S, **Manns B**, Wiebe N, Tonelli M; Alberta Kidney Disease Network. Dialysate potassium and risk of death in chronic hemodialysis patients. *J Nephrol.* 2010;23:33-40
126. Walsh M, Sar A, Lee D, Yilmaz S, Benediktsson H, **Manns B**, Hemmelgarn B. Histopathologic features aid in predicting risk for progression of IgA Nephropathy. *Clin J Am Soc Nephrol.* 2010;e-pub.
127. Walsh M, Jayne D, Moist L, Tonelli M, Pannu N, **Manns B**. Practice pattern variation in oral glucocorticoid therapy after the induction of response in proliferative lupus nephritis. *Lupus.* 2010;19(5):628-33. Epub 2010 Jan 12
128. Tonelli M, Pannu N, **Manns B**. Drug Therapy Article: Oral Phosphate Binders in Patients With Kidney Failure. *N Engl J Med,* 2010, 362:1312-24.
129. Hemmelgarn BR, Zhang J, **Manns BJ**, James MT, Quinn RR, Ravani P, Klarenbach SW, Culleton BF, Krause R, Thorlacius L, Jain AK, Tonelli M. Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate. *JAMA.* 2010; 303: 1151-8.
130. Tai DJ, Lim TW, James MT, **Manns BJ**, Tonelli M, Hemmelgarn BR; Alberta Kidney Disease Network. Cardiovascular effects of Angiotensin converting enzyme inhibition or Angiotensin receptor blockade in hemodialysis: a meta-analysis. *Clin J Am Soc Nephrol.* 2010; 5: 623-30.
131. James MT, Ghali WA, Tonelli M, Faris P, Knudtson ML, Pannu N, Klarenbach SW, **Manns BJ**, Hemmelgarn BR. Acute kidney injury and long-term decline in kidney function following coronary angiography. *Kidney Int.* 2010;78(8):803-9.
132. Schorr M, **Manns BJ**, Culleton B, Walsh M, Klarenbach S, Tonelli M, Sauve L, Chin R, Barnieh L, Hemmelgarn BR; the Alberta Kidney Disease Network. The Effect of Nocturnal and Conventional Hemodialysis on Markers of Nutritional Status: Results From a Randomized Trial. *J Ren Nutr.* 2010 Jul 20. [Epub ahead of print]
133. Barnieh L, McLaughlin K, **Manns BJ**, Klarenbach S, Yilmaz S, Hemmelgarn BR; For the Alberta Kidney Disease Network. Barriers to living kidney donation identified by eligible candidates with end-stage renal disease. *Nephrol Dial Transplant.* 2010 Jul 5.

134. Khangura J, Culleton BF, **Manns BJ**, Zhang J, Barnieh L, Walsh M, Klarenbach SW, Tonelli M, Sarna M, Hemmelgarn BR; Alberta Kidney Disease Network. Association between routine and standardized blood pressure measurements and left ventricular hypertrophy among patients on hemodialysis. *BMC Nephrol*. 2010 Jun 24;11:13.
135. Klarenbach S, **Manns BJ**, Reiman T, Reaume MN, Lee H, Lloyd A, Wiebe N, Hemmelgarn B, Tonelli M. Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer. *Cancer*. 2010 Jul 1;116(13):3224-32.
136. **Manns BJ**, Hodzman A, Zimmerman DL, Mendelssohn DC, Soroka SD, Chan C, Jindal K, Klarenbach S. Canadian Society of Nephrology commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). *Am J Kidney Dis*. 2010 May;55(5):800-12.
137. Ravani P, Parfrey P, MacRae J, James M, Quinn R, Malberti F, Brunori G, Mandolfo S, Tonelli M, Hemmelgarn B, **Manns BJ**, Barrett B. Modeling survival of arteriovenous accesses for hemodialysis: semiparametric versus parametric methods. *Clin J Am Soc Nephrol*. 2010 Jul;5(7):1243-8. Epub 2010 Apr 22.
138. Mustata S, Groeneveld S, Davidson W, Ford G, Kiland K, **Manns BJ**. Effects of exercise training on physical impairment, arterial stiffness, and health-related quality of life in patients with ESRD, *Int Urol Nephrol* 2010; Epub ahead of print.
139. Penz ED, **Manns BJ**, Hebert PC, Stanbrook MB. Governments, pay for smoking cessation. *CMAJ*. 2010; Epub ahead of print.
140. James MT, Ghali WA, Tonelli M, Faris P, Knudtson ML, Pannu N, Klarenbach SW, **Manns BJ**, Hemmelgarn B. Acute kidney injury following coronary angiography I associated with a long-term decline in kidney function. *Kidney Int* 2010; 78:803-9.
141. **Manns BJ**, Hemmelgarn B, Tonelli M, Chiasson C, Au F, Dong J, Klarenbach S. Population based screening for chronic kidney disease: cost effectiveness study. *BMJ* 2010, Nov 8;341:c5869
142. Heitman S, Hilsden R, Au F, Dowden S, **Manns BJ**. Colorectal cancer screening for average risk North Americans: an economic evaluation. *PLOS Med*. 2010; 23;7(11): e1000370.
143. Clement FM, Klarenbach S, Tonelli M, Wiebe N, Hemmelgarn B, **Manns BJ**. An economic evaluation of erythropoiesis-stimulating agents in CKD. *Am J Kidney Dis*. 2010 Dec; 56(6):1050-61. Epub 2010 Oct 8.
144. Heitman SJ, Au F, **Manns BJ**, Pattison P, Hilsden RJ. Nonmedical costs of colorectal cancer screening using CT colonography. *J Am Coll Radiol*. 2010 Dec; 7(12):943-8.

145. James MT, Hemmelgarn BR, Wiebe N, Pannu N, **Manns BJ**, Klarenbach SW, Tonelli M; Alberta Kidney Disease Network. Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. *Lancet*. 2010 Dec 18;376(9758):2096-103. Epub 2010 Nov 20.
146. Rucker D, Hemmelgarn BR, Lin M, **Manns BJ**, Klarenbach SW, Ayyalasomayajula B, James MT, Bello A, Gordon D, Jindal KK, Tonelli M. Quality of care and mortality are worse in chronic kidney disease patients living in remote areas. *Kidney Int*. 2011 Jan; 79(2):210-17. Epub 2010 Oct 6.
147. Tonelli M, Muntner P, Lloyd A, **Manns BJ**, James M, Klarenbach S, Quinn R, Wiebe N, Hemmelgarn B. Using proteinuria and estimated glomerular filtration rate to classify risk in people with chronic kidney disease. *Ann Intern Med* 2011; 4;154(1):12-21
148. Hemmelgarn BR, Moist LM, Lok CE, Tonelli M, **Manns BJ**, Holden RM, LeBlanc M, Faris P, Barre P, Zhang J, Scott-Douglas N. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. *N Engl J Med* 2011;364:303-12.
149. James MT, Ghali WA, Knudtson ML, Ravani P, Tonelli M, Faris P, Pannu N, **Manns BJ**, Klarenbach SW, Hemmelgarn BR. Association between acute kidney injury and cardiovascular and renal outcomes after coronary angiograph. *Circulation*. 2011 123(4): 409-416.
150. **Manns BJ**, Quinn RR. Early dialysis of no benefit to the patient or the health care system. *Am J Kidney Dis*. 2011 May;57(5):649-50.
151. Barnieh L, McLaughlin K, **Manns BJ**, Klarenbach S, Yilmaz S, Taub K, Hemmelgarn BR; Alberta Kidney Disease Network. Evaluation of an education intervention to increase the pursuit of living kidney donation: a randomized controlled trial. *Prog Transplant*. 2011 Mar;21(1):36-42.
152. Tonelli M, **Manns BJ**. Supplementing creatinine-based estimates of risk in chronic kidney disease: is it time? *JAMA*. 2011 Apr 20;305(15):1593-5.
153. Mendelssohn DC, **Manns BJ**. A Proposal for Improving Evidence Generation in Nephrology. *Am J Kidney Dis*. 2011 Jul;58(1):13-8.
154. Padwal R, Klarenbach S, Wiebe N, Birch D, Karmali S, **Manns BJ**, Hazel M, Sharma AM, Tonelli M. Bariatric surgery: a systematic review and network meta-analysis of randomized trials. *Obes Rev*. 2011 Aug;12(8):602-21.
155. McAlister FA, Zhang J, Tonelli M, Klarenbach S, **Manns BJ**, Hemmelgarn BR; on behalf of the Alberta Kidney Disease Network. The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis. *CMAJ*. 2011 Apr 5;183(6):655-662.

156. Clement FM, James MT, Chin R, Klarenbach SW, **Manns BJ**, Quinn RR, Ravani P, Tonelli M, Hemmelgarn BR; Alberta Kidney Disease Network. Validation of a case definition to define chronic dialysis using outpatient administrative data. *BMC Med Res Methodol*. 2011 Mar 1;11:25.
157. Ronksley PE, Hemmelgarn BR, Heitman SJ, Flemons WW, Ghali WA, **Manns BJ**, Faris P, Tsai WH. Excessive daytime sleepiness is associated with increased health care utilization among patients referred for assessment of OSA. *Sleep*. 2011 Mar 1;34(3):363-70.
158. Barnieh L, **Manns BJ**, Klarenbach S, McLaughlin K, Yilmaz S, Hemmelgarn BR. A description of the costs of living and standard criteria deceased donor kidney transplantation. *Am J Transplant*. 2011 Mar;11(3):478-88.
159. Ahmed SB, Ronksley PE, Hemmelgarn BR, Tsai WH, **Manns BJ**, Tonelli M, Klarenbach SW, Chin R, Clement FM, Hanly PJ. Nocturnal hypoxia and loss of kidney function. *PLoS One*. 2011 Apr 29;6(4):e19029.
160. Bello AK, Hemmelgarn B, Lloyd A, James MT, **Manns BJ**, Klarenbach S, Tonelli M; Alberta Kidney Disease Network. Associations among estimated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes. *Clin J Am Soc Nephrol*. 2011 Jun;6(6):1418-26.
161. Ayyalasomayajula B, Wiebe N, Hemmelgarn BR, Bello A, **Manns BJ**, Klarenbach S, Tonelli M. A Novel Technique to Optimize Facility Locations of New Nephrology Services for Remote Areas. *Clin J Am Soc Nephrol*. 2011 Sep.6(9):2157-64. Epub 2011 Aug 4.
162. Padwal R, Klarenbach S, Wiebe N, Hazel M, Birch D, Karmali S, Sharma AM, **Manns BJ**, Tonelli M. Bariatric Surgery: A Systematic Review of the Clinical and Economic Evidence. *J Gen Intern Med*. 2011 Oct. 26 (10): 1183-94.
163. Ronksley PE, Tonelli M, Quan H, **Manns BJ**, James MT, Clement FM, Samuel S, Quinn RR, Ravani P, Brar SS, Hemmelgarn BR; For the Alberta Kidney Disease Network. Validating a case definition for chronic kidney disease using administrative data. *Nephrol Dial Transplant*. 2011 Oct 19. [Epub ahead of print]
164. Conly J, Clement F, Tonelli M, Hemmelgarn B, Klarenbach S, Lloyd A, McAlister FA, Husereau D, Wiebe N, Au F, **Manns BJ**; Alberta Kidney Disease Network. Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk. *CMAJ*. 2011 Nov 8;183(16):E1180-8. Epub 2011 Oct 11.
165. Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B, Klarenbach S, McAlister FA, Wiebe N, **Manns BJ**; Alberta Kidney Disease Network. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. *CMAJ*. 2011 Nov 8;183(16):E1189-202. Epub 2011 Oct 11. Review.

166. Bello A, Thompson S, Lloyd A, Hemmelgarn B, Klarenbach S, **Manns BJ**, Tonelli M; Alberta Kidney Disease Network. Multiple Versus Single and Other Estimates of Baseline Proteinuria Status as Predictors of Adverse Outcomes in the General Population. *Am J Kidney Dis.* 2011 Nov 4.
167. Shurraw S, Hemmelgarn B, Lin M, Majumdar SR, Klarenbach S, **Manns BJ**, Bello A, James M, Turin TC, Tonelli M; Alberta Kidney Disease Network. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease a population-based cohort study. *Arch Intern Med.* 2011 Nov 28;171(21):1920-7.
168. Conley J, Tonelli M, Quan H, **Manns BJ**, Palacios-Derflingher L, Bresee LC, Khan N, Hemmelgarn BR; Alberta Kidney Disease Network. Association Between GFR, Proteinuria, and Adverse Outcomes Among White, Chinese, and South Asian Individuals in Canada. *Am J Kidney Dis.* 2011 Nov 23. [Epub ahead of print]
169. Clement FM, Ghali WA, Rinfret S, **Manns BJ**; the APPROACH Investigators. Economic evaluation of increasing population rates of cardiac catheterization. *BMC Health Serv Res.* 2011 Nov 24;11(1):324.
170. Clement FM, **Manns BJ**, Brownell B, Faris PD, Graham MM, Humphries K, Love M, Knudtson ML, Ghali WA; the APPROACH Investigators. A multi-region assessment of population rates of cardiac catheterization and yield of high-risk coronary artery disease. *BMC Health Serv Res.* 2011 Nov 24;11(1):323.
171. Tonelli M, Klarenbach SW, Lloyd AM, James MT, Bello AK, **Manns BJ**, Hemmelgarn BR. Higher estimated glomerular filtration rates may be associated with increased risk of adverse outcomes, especially with concomitant proteinuria. *Kidney Int.* 2011 Dec;80(12):1306-14.
172. Wiebe N, Klarenbach SW, Chui B, Ayyalasomayajula B, Hemmelgarn BR, Jindal K, **Manns BJ**, Tonelli M; on behalf of the Alberta Kidney Disease Network. Adding Specialized Clinics for Remote-Dwellers with Chronic Kidney Disease: A Cost-Utility Analysis. *Clin J Am Soc Nephrol.* 2012 Jan;7(1):24-34.
174. **Manns BJ**, Tonelli M. The new FDA labeling for ESA--implications for patients and providers. *Clin J Am Soc Nephrol.* 2012 Feb;7(2):348-53.
173. **Manns BJ**, Tonelli M, Zhang J, Campbell DJ, Sargious P, Ayyalasomayajula B, Clement F, Johnson JA, Laupacis A, Lewanczuk R, McBrien K, Hemmelgarn BR. Enrolment in primary care networks: impact on outcomes and processes of care for patients with diabetes. *CMAJ.* 2012 Feb 7;184(2):E144-52
175. Stelfox HT, Hemmelgarn BR, Bagshaw SM, Gao S, Doig CJ, Nijssen-Jordan C, **Manns BJ**. Intensive care unit bed availability and outcomes for hospitalized patients with sudden clinical deterioration. *Arch Intern Med.* 2012 Mar 26;172(6):467-74.



176. **Manns B**, Tonelli M, Culleton B, Faris P, McLaughlin K, Chin R, Gooch K, McAlister FA, Taub K, Thorlacius L, Krause R, Kearns M, Hemmelgarn B; Alberta Kidney Disease Network. A cluster randomized trial of an enhanced eGFR prompt in chronic kidney disease. *Clin J Am Soc Nephrol*. 2012 Apr;7(4):565-72.
177. Tonelli M, Muntner P, Lloyd A, **Manns BJ**, Klarenbach S, Pannu N, James MT, Hemmelgarn BR; Alberta Kidney Disease Network. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. *Lancet*. 2012 Sep 1;380(9844):807-14.
178. Hemmelgarn BR, James MT, **Manns BJ**, O'Hare AM, Muntner P, Ravani P, Quinn RR, Turin TC, Tan Z, Tonelli M; Alberta Kidney Disease Network. Rates of treated and untreated kidney failure in older vs younger adults. *JAMA*. 2012 Jun 20;307(23):2507-15.
179. Tricco AC, Ivers NM, Grimshaw JM, Moher D, Turner L, Galipeau J, Halperin I, Vachon B, Ramsay T, **Manns B**, Tonelli M, Shojania K. Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. *Lancet*. 2012 Jun 16;379(9833):2252-61.
180. Krahn AD, Morillo CA, Kus T, **Manns BJ**, Rose S, Brignole M, Sheldon RS. Empiric pacemaker compared with a monitoring strategy in patients with syncope and bifascicular conduction block--rationale and design of the Syncope: Pacing or Recording in The Later Years (SPRITELY) study. *Europace*. 2012 Jul;14(7):1044-8.
181. Bass A, Ahmed SB, Klarenbach S, Culleton B, Hemmelgarn BR, **Manns B**. The impact of nocturnal hemodialysis on sexual function. *BMC Nephrol*. 2012 Jul 26;13:67.
182. Turin TC, Tonelli M, **Manns BJ**, Ahmed SB, Ravani P, James M, Hemmelgarn BR. Lifetime risk of ESRD. *J Am Soc Nephrol*. 2012 Sep;23(9):1569-78.
183. Turin TC, Tonelli M, **Manns BJ**, Ravani P, Ahmed SB, Hemmelgarn BR. Chronic kidney disease and life expectancy. *Nephrol Dial Transplant*. 2012 Aug;27(8):3182-6.
184. **Manns B**, Laupland K, Tonelli M, Gao S, Hemmelgarn B. Evaluating the impact of a novel restricted reimbursement policy for quinolone antibiotics: A time series analysis. *BMC Health Serv Res*. 2012 Aug 30;12:290.
185. McBrien K, Rabi DM, Campbell N, Barnieh L, Clement F, Hemmelgarn BR, Tonelli M, Leiter LA, Klarenbach SW, **Manns BJ**. Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis. *Arch Intern Med*. 2012 Sep 24;172(17):1296-303.
186. Bello A, Hemmelgarn B, **Manns B**, Tonelli M; Alberta Kidney Disease Network. Use of administrative databases for health-care planning in CKD. *Nephrol Dial Transplant*. 2012 Oct;27 Suppl 3:iii12-8.

187. Bello AK, Hemmelgarn B, Lin M, **Manns B**, Klarenbach S, Thompson S, James M, Tonelli M; for the Alberta Kidney Disease Network. Impact of remote location on quality care delivery and relationships to adverse health outcomes in patients with diabetes and chronic kidney disease. *Nephrol Dial Transplant*. 2012 Oct;27(10):3849-3855.
188. Hemmelgarn BR, **Manns BJ**, Tonelli M; Interdisciplinary Chronic Disease Collaboration. A Decade After the KDOQI CKD Guidelines: A Perspective From Canada. *Am J Kidney Dis*. 2012 Nov;60(5):723-4.
189. Heitman SJ, Hilsden RJ, Au F, Dowden S, **Manns BJ**. Correction: Colorectal Cancer Screening for Average-Risk North Americans: An Economic Evaluation. *PLoS Med*. 2012 Nov;9(11).
190. Hemmelgarn BR, **Manns BJ**, Straus S, Naugler C, Holroyd-Leduc J, Braun TC, Levin A, Klarenbach S, Lee PF, Hafez K, Schwartz D, Jindal K, Ervin K, Bello A, Turin TC, McBrien K, Elliott M, Tonelli M, Collaboration ICDC. Knowledge translation for nephrologists: strategies for improving the identification of patients with proteinuria. *J Nephrol*. 2012 Nov-Dec;25(6):933-43.
191. Barnieh L, Klarenbach S, Gill JS, Caulfield T, **Manns B**. Attitudes Toward Strategies to Increase Organ Donation: Views of the General Public and Health Professionals. *Clin J Am Soc Nephrol*. 2012 Dec;7(12):1956-63
192. Tong A, Palmer S, **Manns B**, Craig JC, Ruospo M, Gargano L, Johnson DW, Hegbrant J, Olsson M, Fishbane S, Strippoli GF. Clinician beliefs and attitudes about home haemodialysis: a multinational interview study. *BMJ Open*. 2012 Dec 12;2(6).
193. Turin TC, Tonelli M, **Manns BJ**, Ahmed SB, Ravani P, James M, Hemmelgarn BR. Proteinuria and Life Expectancy. *Am J Kidney Dis*. 2012 Dec 7.
194. Thompson S, Hemmelgarn B, Wiebe N, Majumdar S, Klarenbach S, Jindal K, **Manns B**, Mortis G, Campbell P, Tonelli M; Alberta Kidney Disease Network. Clinical decision support to improve blood pressure control in hemodialysis patients: a nonrandomized controlled trial. *J Nephrol*. 2012 Nov-Dec;25(6):944-53.
195. Chui BK, **Manns B**, Pannu N, Dong J, Wiebe N, Jindal K, Klarenbach SW. Health Care Costs of Peritoneal Dialysis Technique Failure and Dialysis Modality Switching. *Am J Kidney Dis*. 2013 Jan;61(1):104-11.
196. Tong A, Palmer S, **Manns B**, Craig JC, Ruospo M, Gargano L, Johnson DW, Hegbrant J, Olsson M, Fishbane S, Strippoli GF. The beliefs and expectations of patients and caregivers about home haemodialysis: an interview study. *BMJ Open*. 2013 Jan 24;3(1).
197. Deved V, Jette N, Quan H, Tonelli M, **Manns B**, Soo A, Barnabe C, Hemmelgarn BR; for the Alberta Kidney Disease Network. Quality of Care for First Nations and Non-First Nations People with Diabetes. *Clin J Am Soc Nephrol*. 2013 Feb 28.

198. Ravani P, Palmer SC, Oliver MJ, Quinn RR, Macrae JM, Tai DJ, Pannu NI, Thomas C, Hemmelgarn BR, Craig JC, **Manns B**, Tonelli M, Strippoli GF, James MT. Associations between Hemodialysis Access Type and Clinical Outcomes: A Systematic Review. *J Am Soc Nephrol*. 2013 Feb;24(3):465-73.
199. Campbell DJ, Sargious P, Lewanczuk R, McBrien K, Tonelli M, Hemmelgarn B, **Manns B**. Use of chronic disease management programs for diabetes: In Alberta's primary care networks. *Can Fam Physician*. 2013 Feb;59(2):e86-92.
200. Ronksley PE, Sanmartin C, Quan H, Ravani P, Tonelli M, **Manns B**, Hemmelgarn BR. Association between perceived unmet health care needs and risk of adverse health outcomes among patients with chronic medical conditions. *Open Med*. 2013 Feb 26;7(1):e21-30. Print 2013.
201. Thompson S, Bello A, Wiebe N, **Manns B**, Hemmelgarn B, Klarenbach S, Pelletier R, Tonelli M; Alberta Kidney Disease Network. Quality-of-Care Indicators Among Remote-Dwelling Hemodialysis Patients: A Cohort Study. *Am J Kidney Dis*. 2013 Mar 18
202. McBrien KA, **Manns BJ**. Haemodiafiltration: not effective or cost-effective compared with haemodialysis. *Nephrol Dial Transplant*. 2013 April
203. Tonelli M, Muntner P, Lloyd A, **Manns B**, Klarenbach S, Pannu N, James M, Hemmelgarn B; Alberta Kidney Disease Network. Association between LDL-C and Risk of Myocardial Infarction in CKD. *J Am Soc Nephrol*. 2013 May;24(6):979-86. Epub 2013 May.
204. McBrien KA, **Manns BJ**, Chui B, Klarenbach SW, Rabi D, Ravani P, Hemmelgarn B, Wiebe N, Au F, Clement F. Health Care Costs in People With Diabetes and Their Association With Glycemic Control and Kidney Function. *Diabetes Care*. 2013 May;36(5):1172-80.
205. Elliott MJ, James MT, Quinn RR, Ravani P, Tonelli M, Palacios-Derflingher L, Tan Z, **Manns BJ**, Kline GA, Ronksley PE, Hemmelgarn BR. Estimated GFR and Fracture Risk: A Population-Based Study. *Clin J Am Soc Nephrol*. 2013 May.
206. McBrien KA, **Manns B**. Approach to economic evaluation in primary care: review of a useful tool for primary care reform. *Can Fam Physician*. 2013 Jun;59(6):619-27.
207. Wong BC, Ravani P, **Manns BJ**, Lewin A, Zhang X, Chin R, Hemmelgarn BR, Tonelli M, Oliver MJ, Quinn RR. Association of a Change in Erythropoiesis-Stimulating Agent Dose During Hospitalization and Subsequent Hemoglobin Levels and Transfusions in Hemodialysis Patients. *Am J Kidney Dis*. 2013 Jul 12. [Epub ahead of print]
208. Ravani P, Gillespie BW, Quinn RR, Macrae J, **Manns B**, Mendelssohn D, Tonelli M, Hemmelgarn B, James M, Pannu N, Robinson BM, Zhang X, Pisoni R. Temporal Risk Profile for Infectious and Noninfectious Complications of Hemodialysis Access. *J Am Soc Nephrol*. 2013 Jul 11. [Epub ahead of print]

209. Faruque LI, Hemmelgarn BR, Wiebe N, **Manns BJ**, Ravani P, Klarenbach S, Pelletier R, Tonelli M; Alberta Kidney Disease Network. Factors associated with initiation of chronic renal replacement therapy for patients with kidney failure. *Clin J Am Soc Nephrol*. 2013 Jul;8(8):1327-35.
210. Turin TC, James M, Ravani P, Tonelli M, **Manns BJ**, Quinn R, Jun M, Klarenbach S, Hemmelgarn BR. Proteinuria and Rate of Change in Kidney Function in a Community-Based Population. *J Am Soc Nephrol*. 2013 Jul 5. [Epub ahead of print]
211. James MT, Tonelli M, Ghali WA, Knudtson ML, Faris P, **Manns BJ**, Pannu N, Galbraith PD, Hemmelgarn BR; Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) and Alberta Kidney Disease Network Investigators. Renal outcomes associated with invasive versus conservative management of acute coronary syndrome: propensity matched cohort study. *BMJ*. 2013 Jul 5;347:f4151.
212. Schorr M, Hemmelgarn BR, Tonelli M, Soo A, **Manns BJ**, Bresee LC; Alberta Kidney Disease Network. Assessment of Serum Creatinine and Kidney Function among Incident Metformin Users. *Can J Diabetes*. 2013 Aug;37(4):226-30.
213. Tang KL, Ghali WA, **Manns BJ**. Addressing cost-related barriers to prescription drug use in Canada. *CMAJ*. 2013 Sep 16. [Epub ahead of print]
214. Ronksley PE, Ravani P, Sanmartin C, Quan H, **Manns B**, Tonelli M, Hemmelgarn BR. Patterns of engagement with the health care system and risk of subsequent hospitalization amongst patients with diabetes. *BMC Health Serv Res*. 2013 Oct 9;13:399.
215. Hemmelgarn BR, Zhang J, **Manns BJ**, Tonelli M. Multidisciplinary care and immortal time bias. *Kidney Int*. 2013 Nov;84(5):1052.
216. **Manns B**, Braun T, Edwards A, Grimshaw J, Hemmelgarn B, Husereau D, Ivers N, Johnson J, Long S, McBrien K, Naugler C, Sargious P, Straus S, Tonelli M, Tricco A, Yu C for the Alberta Innovates – Health Solutions Interdisciplinary Chronic Disease Collaboration. Identifying strategies to improve diabetes care in Alberta, Canada using the knowledge-to-action cycle: Results of a collaborative workshop. *CMAJ Open* 2013 Nov 20.
217. Majumdar SR, Hemmelgarn BR, Lin M, McBrien K, **Manns BJ**, Tonelli M. Hypoglycemia Associated With Hospitalization and Adverse Events in Older People: Population-based cohort study. *Diabetes Care*. 2013 Nov;36(11):3585-90.
218. Bello A, Padwal R, Lloyd A, Hemmelgarn B, Klarenbach S, **Manns B**, Tonelli M; Alberta Kidney Disease Network. Using linked administrative data to study periprocedural mortality in obesity and chronic kidney disease (CKD). *Nephrol Dial Transplant*. 2013 Nov;28 Suppl 4:iv57-iv64.

219. Moist LM, Troyanov S, White CT, Wazny LD, Wilson JA, McFarlane P, Harwood L, Sood MM, Soroka SD, Bass A, **Manns BJ**. Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. *Am J Kidney Dis*. 2013 Nov;62(5):860-73.
220. Barnieh L, **Manns B**, Harris A, Blom M, Donaldson C, Klarenbach S, Husereau D, Lorenzetti D, Clement F. A Synthesis of Drug Reimbursement Decision-Making Processes in Organisation for Economic Co-operation and Development Countries. *Value Health*. 2014 Jan;17(1):98-108.
221. Samuel SM, Palacios-Derflingher L, Tonelli M, **Manns B**, Crowshoe L, Ahmed SB, Jun M, Saad N, Hemmelgarn BR; Alberta Kidney Disease Network. Association between First Nations ethnicity and progression to kidney failure by presence and severity of albuminuria. *CMAJ*. 2014 Feb 4;186(2):E86-94.
222. Sood MM, Tangri N, Hiebert B, Kappel J, Dart A, Levin A, **Manns B**, Molzahn A, Naimark D, Nessim SJ, Rigatto C, Soroka SD, Zappitelli M, Komenda P; Canadian Kidney Knowledge Translation; Generation Network. Geographic and facility-level variation in the use of peritoneal dialysis in Canada: a cohort study. *CMAJ Open*. 2014 Mar 27;2(1):E36-44.
223. Weaver RG, **Manns BJ**, Tonelli M, Sanmartin C, Campbell DJ, Ronksley PE, Lewanczuk R, Braun TC, Hennessy D, Hemmelgarn BR. Access to primary care and other health care use among western Canadians with chronic conditions: a population-based survey. *CMAJ Open*. 2014 Mar 7;2(1):E27-34.
224. Klarenbach S, Tonelli M, Pauly R, Walsh M, Culleton B, So H, Hemmelgarn B, **Manns B**. Economic evaluation of frequent home nocturnal hemodialysis based on a randomized controlled trial. *J Am Soc Nephrol*. 2014 Mar;25(3):587-94.
225. Mann BS, Barnieh L, Tang K, Campbell DJ, Clement F, Hemmelgarn B, Tonelli M, Lorenzetti D, **Manns BJ**. Association between drug insurance cost sharing strategies and outcomes in patients with chronic diseases: a systematic review. *PLoS One*. 2014 Mar 25;9(3):e89168.
226. Barnieh L, Clement F, Harris A, Blom M, Donaldson C, Klarenbach S, Husereau D, Lorenzetti D, **Manns B**. A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development. *PLoS One*. 2014 Mar 11;9(3):e90434.
227. Nesrallah G, Barnieh L, **Manns B**, Clase C, Mendelssohn D, Guyatt G. A charitable donation incentive did not increase physician survey response rates in a randomized trial. *J Clin Epidemiol*. 2014 Apr;67(4):482-3.
228. Afshar AE, Weaver RG, Lin M, Allan M, Ronksley PE, Sanmartin C, Lewanczuk R, Rosenberg M, **Manns B**, Hemmelgarn B, Tonelli M; Interdisciplinary Chronic Disease Collaboration. Capacity and willingness of patients with chronic noncommunicable diseases to use information technology to help manage their condition: a cross-sectional study. *CMAJ Open*. 2014 Apr 16;2(2):E51-9.

229. Ronksley PE, Sanmartin C, Campbell DJT, Weaver RG, Allan GM, McBrien K, Tonelli M, **Manns B**, Hennessy D, Hemmelgarn B. Perceived barriers to primary care among Western Canadians with chronic disease. *Health Rep.* 2014 Apr 16;25(4):3-10.
230. Tonelli M, Muntner P, Lloyd A, **Manns B**, Klarenbach S, Pannu N, James M, Hemmelgarn B; Alberta Kidney Disease Network. Impact of Age on the Association Between CKD and the Risk of Future Coronary Events. *Am J Kidney Dis.* 2014 Apr 18.
231. Wiebe N, Klarenbach SW, Allan GM, **Manns BJ**, Pelletier R, James MT, Bello A, Hemmelgarn BR, Tonelli M; Alberta Kidney Disease Network. Potentially Preventable Hospitalization as a Complication of CKD: A Cohort Study. *Am J Kidney Dis.* 2014 Apr 12.
232. Campbell DJ, Ronksley PE, **Manns BJ**, Tonelli M, Sanmartin C, Weaver RG, Hennessy D, King-Shier K, Campbell T, Hemmelgarn BR; Interdisciplinary Chronic Disease Collaboration. The association of income with health behavior change and disease monitoring among patients with chronic disease. *PLoS One.* 2014 Apr 10;9(4):e94007.
233. Campbell DJ, King-Shier K, Hemmelgarn BR, Sanmartin C, Ronksley PE, Weaver RG, Tonelli M, Hennessy D, **Manns BJ**. Self-reported financial barriers to care among patients with cardiovascular-related chronic conditions. *Health Rep.* 2014 May 21;25(5):3-12.
234. **Manns B**, Hemmelgarn B, Lillie E, Dip SC, Cyr A, Gladish M, Large C, Silverman H, Toth B, Wolfs W, Laupacis A. Setting Research Priorities for Patients on or Nearing Dialysis. *Clin J Am Soc Nephrol.* 2014 May 15
235. Penz ED, Mishra EK, Davies HE, **Manns BJ**, Miller RF, Rahman NM. Comparing Cost of Indwelling Pleural Catheter vs. Talc Pleurodesis for Malignant Pleural Effusion. *Chest.* 2014 May 15.
236. Nesrallah G, **Manns B**. Do socioeconomic factors affect dialysis modality selection? *Clin J Am Soc Nephrol.* 2014 May;9(5):837-9.
237. Sood MM, **Manns B**, Nesrallah G; Canadian Kidney Knowledge Translation, Generation Network. Using the knowledge-to-action framework to guide the timing of dialysis initiation. *Curr Opin Nephrol Hypertens.* 2014 May;23(3):321-7.
238. Weaver RG, Hemmelgarn BR, Rabi DM, Sargious PM, Edwards AL, **Manns BJ**, Tonelli M, James MT. Association between participation in a brief diabetes education programme and glycaemic control in adults with newly diagnosed diabetes. *Diabet Med.* 2014 Jun 3. [Epub ahead of print]
239. Tang KL, Barnieh L, Mann B, Clement F, Campbell DJ, Hemmelgarn BR, Tonelli M, Lorenzetti D, **Manns BJ**. A systematic review of value-based insurance design in chronic diseases. *Am J Manag Care.* 2014 Jun;20(6):e229-41.
240. **Manns B**, Scott-Douglas N, Tonelli M, Ravani P, LeBlanc M, Dorval M, Holden R, Moist L, Lok C, Zimmerman D, Au F, Hemmelgarn B. An economic evaluation of rt-PA locking solution in dialysis catheters. *JASN* 2014 July 10. [Epub ahead of print]

241. Bresee LC, Knudtson ML, Zhang J, Crowshoe LL, Ahmed SB, Tonelli M, Ghali WA, Quan H, **Manns B**, Fabreau G, Hemmelgarn BR; Alberta Kidney Disease Network (AKDN) and the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH). Likelihood of coronary angiography among First Nations patients with acute myocardial infarction. *CMAJ*. 2014 July 8;186(10):E372-80.
242. Ivers N, Tricco AC, Trikalinos TA, Dahabreh IJ, Danko KJ, Moher D, Straus SE, Lavis JN, Yu CH, Shojania K, **Manns B**, Tonelli M, Ramsay T, Edwards A, Sargious P, Paprica A, Hillmer M, Grimshaw JM. Seeing the forests and the trees-innovative approaches to exploring heterogeneity in systematic reviews of complex interventions to enhance health system decision-making: a protocol. *Syst Rev*. 2014 Aug 12;3(1):88.
243. Turin TC, James MT, Jun M, Tonelli M, Coresh J, **Manns BJ**, Hemmelgarn BR. Short-term change in eGFR and risk of cardiovascular events. *J Am Heart Assoc*. 2014 Sep 11;3(5).
244. Barnieh L, Yilmaz S, McLaughlin K, Hemmelgarn BR, Klarenbach S, **Manns BJ**, For The Alberta Kidney Disease Network. The cost of kidney transplant over time. *Prog Transplant*. 2014 Sep;24(3):257-62.
245. Campbell DJ, Lacny SL, Weaver RG, **Manns BJ**, Tonelli M, Barnabe C, Hemmelgarn BR. Age modification of diabetes-related hospitalization among First Nations adults in Alberta, Canada. *Diabetol Metab Syndr*. 2014 Oct 2;6(1):108.
246. Sood MM, **Manns B**, Dart A, Hiebert B, Kappel J, Komenda P, Molzahn A, Naimark D, Nessim S, Rigatto C, Soroka S, Zappitelli M, Tangri N; Canadian Kidney Knowledge Translation and Generation Network (CANN-NET). Variation in the Level of eGFR at Dialysis Initiation across Dialysis Facilities and Geographic Regions. *Clin J Am Soc Nephrol*. 2014 Oct 7;9(10):1747-56.
247. Negrón ME, Kaplan GG, Barkema HW, Eksteen B, Clement F, **Manns BJ**, Coward S, Panaccione R, Ghosh S, Heitman SJ. Colorectal cancer surveillance in patients with inflammatory bowel disease and primary sclerosing cholangitis: an economic evaluation. *Inflamm Bowel Dis*. 2014 Nov;20(11):2046-55.
248. Klarenbach SW, Tonelli M, Chui B, **Manns BJ**. Economic evaluation of dialysis therapies. *Nat Rev Nephrol*. 2014 Nov;10(11):644-652.
249. Barnieh L, Jun M, Laupacis A, **Manns B**, Hemmelgarn B. Determining Research Priorities Through Partnership with Patients: An Overview. *Semin Dial*. 2014 Nov 30.
250. Wolfger B, **Manns BJ**, Barkema HW, Schwartzkopf-Genswein KS, Dorin C, Orsel K. Evaluating the cost implications of a radio frequency identification feeding system for early detection of bovine respiratory disease in feedlot cattle. *Prev Vet Med*. 2014 Dec 11.
251. Tong A, Chando S, Crowe S, **Manns B**, Winkelmayr WC, Hemmelgarn B, Craig JC. Research Priority Setting in Kidney Disease: A Systematic Review. *Am J Kidney Dis*. 2015 Jan 9.

252. Jun M, Turin TC, Woodward M, Perkovic V, Lambers Heerspink HJ, **Manns BJ**, Tonelli M, Hemmelgarn BR. Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis. *J Am Soc Nephrol*. 2015 Jan 2. pii: ASN.
253. Bello AK, Levin A, **Manns BJ**, Feehally J, Drueke T, Faruque L, Hemmelgarn BR, Kernahan C, Mann J, Klarenbach S, Remuzzi G, Tonelli M; Kidney Health for Life Initiative. Effective CKD Care in European Countries: Challenges and Opportunities for Health Policy. *Am J Kidney Dis*. 2015 Jan;65(1):15-25.
254. Akbari A, Clase CM, Acott P, Battistella M, Bello A, Feltmate P, Grill A, Karsanji M, Komenda P, Madore F, **Manns BJ**, Mahdavi S, Mustafa RA, Smyth A, Welcher ES. Canadian Society of Nephrology Commentary on the KDIGO Clinical Practice Guideline for CKD Evaluation and Management. *Am J Kidney Dis*. 2015 Feb;65(2):177-205.
255. Jun M, James MT, **Manns BJ**, Quinn RR, Ravani P, Tonelli M, Perkovic V, Winkelmayr WC, Ma Z, Hemmelgarn BR; Alberta Kidney Disease Network. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. *BMJ*. 2015 Feb 3;350:h246.
256. Thompson S, James M, Wiebe N, Hemmelgarn B, **Manns B**, Klarenbach S, Tonelli M; for the Alberta Kidney Disease Network. Cause of Death in Patients with Reduced Kidney Function. *J Am Soc Nephrol*. 2015 Mar 2.
257. **Manns, BJ**. Evidence-based decision-making 7: knowledge translation. *Methods Mol Biol*. March 2015;1281:485-500.
258. **Manns, BJ**. Health economics in clinical research. *Methods Mol Biol*. March 2015;1281:315-30.
259. Kelly E, Ivers N, Zawi R, Barnieh L, Manns B, Lorenzetti DL, Nicholas D, Tonelli M, Hemmelgarn B, Lewanczuk R, Edwards A, Braun T, McBrien KA. Patient navigators for people with chronic disease: protocol for a systematic review and meta-analysis. *Syst Rev*. 2015 Mar 14;4:28.
260. Thompson S, James M, Wiebe N, Hemmelgarn B, **Manns B**, Klarenbach S, Tonelli M; for the Alberta Kidney Disease Network. Cause of Death in Patients with Reduced Kidney Function. *J Am Soc Nephrol*. 2015 Mar 2. pii: ASN.2014070714. [Epub ahead of print]
261. Tonelli M, Wiebe N, Fortin M, Guthrie B, Hemmelgarn BR, James MT, Klarenbach SW, Lewanczuk R, **Manns BJ**, Ronksley P, Sargious P, Straus S, Quan H; Alberta Kidney Disease Network. Methods for identifying 30 chronic conditions: application to administrative data. *BMC Med Inform Decis Mak*. 2015 Apr 17;15:31.
262. Tonelli M, Wiebe N, Thompson S, Kinniburgh D, Klarenbach SW, Walsh M, Bello AK, Faruque L, Field C, **Manns BJ**, Hemmelgarn BR; Alberta Kidney Disease Network. Trace element supplementation in hemodialysis patients: a randomized controlled trial. *BMC Nephrol*. 2015 Apr 11;16:52.



263. James MT, Pannu N, Barry R, Karsanji D, Tonelli M, Hemmelgarn BR, **Manns BJ**, Bagshaw SM, Stelfox HT, Dixon E. A modified Delphi process to identify process of care indicators for the identification, prevention and management of acute kidney injury after major surgery. *Can J Kidney Health Dis.* 2015 Apr 9;2:11.
264. Tonelli M, Molzahn AE, Wiebe N, Davison SN, Gill JS, Hemmelgarn BR, **Manns BJ**, Pannu N, Pelletier R, Thompson S, Klarenbach SW; Alberta Kidney Disease Network. Relocation of remote-dwellers living with hemodialysis: a time trade-off survey. *Nephrol Dial Transplant.* 2015 Jun 1. pii: gfv112. [Epub ahead of print]
265. Harrison TG, Wick J, Ahmed SB, Jun M, **Manns BJ**, Quinn RR, Tonelli M, Hemmelgarn BR. Patients with chronic kidney disease and their intent to use electronic personal health records. *Can J Kidney Health Dis.* 2015 Jun 9;2:23.

### **Working Papers / Papers produced for External Health Agencies:**

1. **Manns BJ**, Johnson JA, Taub K, Mortis G, Ghali WA, Donaldson C. Quality of life in patients with End-Stage Renal Disease on Hemodialysis or Peritoneal Dialysis: What are the important determinants? Institute of Health Economics Working paper 02-05, 2002.
2. Helen Lee, **Braden J. Manns**, Christopher James Doig, David Johnson, Cam Donaldson. A cost-effectiveness analysis of recombinant human activated protein C for severe sepsis in the Intensive Care Unit. ASCHUR / Institute of Health Economics Working Paper 02-06, 2002.
3. Browman G, **Manns B**, Hagen N, Chambers C. Five Steps: Evaluation framework for ranking cancer drugs for funding decisions in Alberta. Alberta Cancer Board, 2006.
4. **BJ Manns** et al, Sevelamer in Patients with End-Stage Renal Disease: A systematic review and Economic evaluation. CADTH report 71, Nov 2006.
5. Tonelli M, Klarenbach S, Wiebe N, Shrive F, Doig C, **Manns B**. A Systematic Review and Economic Evaluation of Continuous Renal Replacement Therapy (CRRT) in Adult Patients with Acute Renal Failure (ARF). CADTH report, 2007.
6. Tonelli M, Klarenbach S, Wiebe N, Shrive F, Hemmelgarn B, **Manns B**. Erythropoiesis-Stimulating Agents for Anemia of Chronic Kidney Disease: Systematic Review and Economic Evaluation [Technology report number 106]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008.
7. Marcello Tonelli, Anita Lloyd, Helen Lee, Natasha Wiebe, Brenda Hemmelgarn, Anthony Reiman, **Braden Manns**, Neil Reaume, Scott Klarenbach. Erythropoiesis-Stimulating

Agents for Anemia of Cancer or of Chemotherapy: Systematic Review and Economic Evaluation [Technology Report]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.

8. Ho C, Heitman S, Membe SK, Morrison A, Moulton K, **Manns B**, Au F, Reed M, Hilsden R. Computed tomographic colonography for colorectal cancer screening in an average risk population: Systematic review and economic evaluation [Technology report number 114]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008.